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Abstract: Iminosugars are an important class of natural prod-
ucts and have been subject to extensive studies in organic syn-
thesis, bioorganic chemistry and medicinal chemistry, yet only
a limited number of these studies are on glycosylated imino-
sugars. Here, a general route of synthesis is presented towards
glycosylated 1-deoxynojirimycin derivatives based on the oxid-
Introduction
Iminosugars have received considerable interest in the past
decades because of their potential to inhibit glycoprocessing
enzymes.[1] A relatively unexplored class of iminosugars com-
prises the glycosylated deoxynojirimycin derivatives. Whereas
monosaccharide iminosugars act as exoglycosidase inhibitors
and sometimes also as glycosyl transferase inhibitors, imino-
sugars functionalized with a monosaccharide or an oligosac-
charide may well act as inhibitors of another major class of
glycoprocessing enzymes: endoglycosidases. Glycosylated
iminosugars have been isolated from plants and microorga-
nisms, often organisms that also produce 1-deoxynojirimycin
(DNJ).[2] However, the natural abundance of such glycosylated
iminosugars is often quite low, and the synthesis of glycosyl-
ated DNJ derivatives is therefore an attractive alternative. Three
conceptual approaches can be discerned by means of which
glycosylated DNJ have been prepared. These are 1) enzymatic
glycosylation of DNJ derivatives;[3] 2) chemical glycosylation[4]
of DNJ derivatives and 3) strategies[5] based on disaccharide
(or oligosaccharide) entities as starting material. The enzymatic
glycosylation of DNJ derivatives has been accomplished using
glycohydrolases as catalysts in transglycosylation of an appro-
priate donor glycoside. One of the earliest endeavors in this
vein comprises the synthesis of malto-DNJ using α-cyclodextrin
as glucose donor and bacillus macerans amylase as transglyc-
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ation–reductive amination protocol that in the past has also
been shown to be a versatile route towards 1-deoxynojirimycin.
The strategy can be applied on commercial disaccharides, as
shown in four examples, as well as on disaccharides that are
not commercially available and are synthesized for this purpose,
as shown by a fifth example.
osylase.[3a] Following these studies, it was shown that a variety
of alternative glycosides including p-nitrophenyl-α-D-galact-
ose,[3b] UDP-glucose,[3c] and lactose[3d] are effective donor glyc-
osides as well, expanding the methodology to yield a variety of
glycosylated DNJ derivatives. Enzymatic approaches hold sev-
eral advantages, including mild reaction conditions, readily
available starting materials and short reaction sequences. How-
ever, enzymatic synthesis also has its limitations, including
structural diversity that can be obtained in general and, in par-
ticular in the use of transglycosylations, the potential formation
of structural isomers. For example, when cellobiose was chosen
as glycosyl donor and yeast -glucosidase as the transglycosyl-
ase catalyst, a mixture of glycosylated DNJs was obtained.[3e]
Because of their similar chemical and physical properties, sepa-
ration of such a mixture can be a challenge. Chemical glycosyl-
ation forms an attractive alternative for enzymatic glycosylation
of DNJ.[4] In chemical glycosylation approaches, part of the
hydroxyl groups in the acceptor (DNJ) are selectively protected,
leaving the hydroxyl to be modified available for glycosylation
using an appropriate donor and activation strategy. Since the
synthesis of a donor and acceptor may take quite a few protec-
tion and deprotection steps, this strategy may be – compared
to enzymatic synthesis – somewhat long and tedious. The third
conceptual strategy towards glycosylated DNJ derivatives that
has been studied to some extent comprises the use of disac-
charides as starting material.[5] In this strategy multistep prepa-
ration of the donor and acceptor moieties is avoided, but the
caveat is that appropriate disaccharide starting materials should
be available. The transformation of disaccharides into glycosyl-
ated DNJ derivatives described in this work is rooted in the
double reductive amination strategy earlier applied by us,[6] and
others,[7] for the synthesis of DNJ. In this strategy, the anomeric
center of a partially protected disaccharide is selectively ex-
posed, and the hemi-acetal reduced to generate the key 1,5-
diol intermediate. This diol is oxidized to the keto-aldehyde,
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which in a double reductive amination event is transformed
into the target glycosylated DNJ derivative. An important fea-
ture of this Scheme is the recovery of the stereo-center at C5
of the newly formed iminosugar, which works well when the
glucopyranose configuration is the desired one.
Results and Discussion
The synthesis of 6-O-(α-D-galactopyranosyl)-1-deoxynojirimycin
(9, 1-deoxy-melibio-DNJ) is depicted in Scheme 1 and reveals
the general strategy we also applied for the preparation of the
ensuing aza-disaccharides (14, 19, 24 and 29, see Scheme 2,
Scheme 3, Scheme 4 and Scheme 5, respectively).
Scheme 1. Reagents and conditions: a) Ac2O, NaOAc, reflux, 90 %. b) PhSH,
BF3·OEt2, CH2Cl2, 82 %. c) 1) NaOMe, MeOH; 2) NaH, BnBr, DMF, 50 % over
the two steps. d) NIS, TFA, CH2Cl2, 77 %. e) LiAlH4, THF, 74 %. f ) oxalyl chloride,
DMSO, Et3N, –78 °C. g) HCO2NH4, Na2SO4, NaCNBH3, h) H2, Pd/C (10 %), DMF/
MeOH, HCl (aq), 50 % over the three steps.
Treatment of melibiose 1, which is commercially available,
with sodium acetate in refluxing acetic anhydride afforded per-
acetylated melibiose 2, which was treated with thiophenol and
BF3·OEt2 to give phenylthiomelibioside 3 in 74 % yield over the
two steps. Zémplen deacetylation followed by benzylation
yielded perbenzylated thiomelibiose 4, the thiophenyl group in
which could be removed using conditions we developed previ-
ously[8] (treatment with N-iodosuccinimide and trifluoroacetic
acid) to yield lactol 5 as the key intermediate in 39 % yield over
the three steps. In the next step, the hemiacetal moiety in 5
was reduced (lithium aluminum hydride) to give diol 6, which
was oxidized to keto-aldehyde 7 using Swern conditions. Dou-
ble reductive amination with concomitant regeneration of the
chiral center at C-5 (DNJ ring, glucopyranose numbering) was
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Scheme 2. Reagents and conditions: a) Ac2O, NaOAc, reflux, 94 %. b) 1) PhSH,
BF3·OEt2, CH2Cl2; 2) NaOMe, MeOH; 3) NaH, BnBr, DMF; 4) NIS, TFA, CH2Cl2,
50 % over the four steps. c) 1) LiAlH4, THF; 2) oxalyl chloride, DMSO, Et3N,
–78 °C. d) HCO2NH4, Na2SO4, NaCNBH3; 2) H2, Pd/C (10 %), DMF/MeOH, HCl
(aq), 23 % over the four steps.
Scheme 3. Reagents and conditions: a) Ac2O, NaOAc, reflux, 100 %. b) 1)
PhSH, BF3·OEt2, CH2Cl2; 2) NaOMe, MeOH; 3) NaH, BnBr, DMF; 4) NIS, TFA,
CH2Cl2, 65 % over the four steps. c) 1) LiAlH4, THF; 2) oxalyl chloride, DMSO,
Et3N, –78 °C. d) HCO2NH4, Na2SO4, NaCNBH3; 2) H2, Pd/C (10 %), DMF/MeOH,
HCl (aq), 11 % over the four steps.
Scheme 4. Reagents and conditions: a) Ac2O, NaOAc, reflux, 98 %. b) 1) PhSH,
BF3·OEt2, CH2Cl2; 2) NaOMe, MeOH; 3) NaH, BnBr, DMF; 4) NIS, TFA, CH2Cl2,
73 % over the four steps. c) 1) LiAlH4, THF; 2) oxalyl chloride, DMSO, Et3N,
–78 °C. d) HCO2NH4, Na2SO4, NaCNBH3; 2) H2, Pd/C (10 %), DMF/MeOH, HCl
(aq), 21 % over the four steps.
accomplished using ammonium formate and sodium cyano-
borohydride to yield per-O-benzylated 1-deoxy-melibio-nojiri-
mycin 8 (52 % yield, three steps). The chirality of carbon C5 of
the piperidine moiety was unambiguously established by pro-
ton NMR, revealing that, as expected, the iminosugar moiety
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Scheme 5. Reagents and conditions: a) TMSOTf, CH2Cl2, 0 °C, 69 %. b) 1) TBAF,
THF; 2) pTsOH, CH2Cl2; 3) NaH, BnBr, DMF, 57 % over the three steps.
c) 1) NIS, TFA, CH2Cl2; 2) LiAlH4, THF; 3) oxalyl chloride, DMSO, Et3N, –78 °C;
4) HCO2NH4, Na2SO4, NaCNBH3; 5) H2, Pd/C (10 %), DMF/MeOH, HCl (aq), 8 %
over the five steps.
had the D-gluco-configuration (as in DNJ). The coupling con-
stants between H-4 and H-5 (9.5 Hz) and between H-2 and H-3
(9.1 Hz) are in full agreement with the stereochemistry of 8,
and the stereochemical outcome of the double reductive amin-
ation step is therefore as was observed previously for the syn-
thesis of DNJ using the same sequence of events (reduction of
the hemi-acetal in 2,3,4,6-tetra-O-benzyl-glucopyranose, fol-
lowed by Swern oxidation of both primary and secondary alco-
hol and finally double reductive amination of the intermediate
5-keto-aldehyde[6c]). Removal of the benzyl groups in 8 by
palladium-catalyzed hydrogenation gave the target imino-
disaccharide 9 in 11 % overall yield starting from 1.
The synthesis strategy applied for the assembly of 4-O-(α-
D-glucopyranosyl)-1-deoxynojirimycin (14, 1-deoxy-malto-DNJ)
was identical as described for the synthesis of 8, starting from
maltose (10).
Lactol 12 was uneventfully obtained from maltose 10 in a
yield of 47 % over the five steps. Lithium aluminum hydride
reduction of 12 followed by Swern oxidation (12 to 13) of both
primary and secondary alcohol and double reductive amination
produced fully protected 1-deoxy-malto-DNJ (33 % yield, three
steps). The stereochemical outcome in synthesizing 32 was
again demonstrated by proton NMR spectroscopy (see the Ex-
perimental Section). The benzyl groups were removed by palla-
dium-catalyzed hydrogenolysis to form target iminosugar 14 in
11 % overall yield starting from 10.
The synthesis of 4-O-(-D-galactopyranosyl)-1-deoxynojiri-
mycin 19 (1-deoxy-lacto-DNJ) starts with lactose 15 (Scheme 3),
which is one of the cheapest disaccharide known and is a side
product of the dairy industry. Peracetylation of lactose 15 fol-
lowed by generation of the thiolactoside, Zémplen removal of
the acetates, benzyl protection and NIS/TFA thioglycoside
hydrolysis as described before afforded lactol 17. In the next
series of events, lactol 17 was reduced (lithium aluminum
hydride), subjected to Swern oxidation (17 to 18) followed by
a double reductive amination and treatment with palladium on
carbon and dihydrogen gas to give the desired imino-disacchar-
ide 19 in 14 % overall yield starting from 15.
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Starting from cellobiose 20, 4-O-(-D-glucopyranosyl)-1-
deoxynojirimycin 24 (1-deoxy-cellobio-DNJ) was obtained
(Scheme 4) in 10 % overall yield following the sequence of
events as described for the synthesis of 9 (1-deoxy-melobio-
DNJ).
The examples described above (compounds 9, 14, 19 and
24, Scheme 1, Scheme 2, Scheme 3, and Scheme 4) comprise
the use of cheap, readily available disaccharides featuring a
glucopyranose moiety at the reducing end as starting material.
Obviously, many disaccharides other than the ones used can be
envisaged as starting material and that have a similar lay-out:
a glycosylated glucopyranose. Besides making use of available
disaccharides of this nature, one can also synthesize these by
chemical glycosylation of a partially protected glucopyranose
moiety, as is exemplified in Scheme 5.
Gal-DNJ [2-O-(α-D-galactopyranosyl)-1-deoxynojirimycin] 29
is one of several glycosylated DNJ derivatives (including 1-de-
oxy-melobio-DNJ, 24) found both in mulberry trees (Morus alba
L.) and silkworms (Bombyx mori L.) that feed on leaves from
these trees, and is a moderately potent inhibitor of digestive
glycosidases (maltase, sucrose) in rat.[2c] In order to access com-
pound 29 following the general procedure subject of this work,
the appropriately protected disaccharide 28 is required, which
on paper can be derived from 2-O-(α-D-galactopyranosyl)-gluc-
ose. In contrast to other disaccharides, however, this disacchar-
ide is scarce and not commercially available, and thus the route
of synthesis as outlined in Scheme 5 is followed.
Treatment of the donor monosaccharide, N-phenyl-trifluoro-
methyl galactose imidate 25 (prepared following the literature
procedures,[10] see the Experimental Section) and the acceptor
monosaccharide, thioglycopyranoside 26 (see for its prepara-
tion[11] the Experimental Section) with trimethylsilyl trifluoro-
methanesulfonate in dichloromethane at 0 °C gave fully pro-
tected disaccharide 27 in 69 % yield and excellent α-stereo-
selectivity, as expected for glycosylations of 4–6-O-silylidene
protected galactopyranose donors.[12] Sequential removal of
the silylidene protective group (treatment with tetrabutyl
ammonium fluoride) and the benzylidene protective group
(treatment with catalytic p-toluenesulfonic acid) followed by
benzylation of the thus liberated four hydroxyl groups afforded
fully benzylated phenylthiodisaccharide 28. This disaccharide
was then transformed into Gal-DNJ 29 following the estab-
lished sequence of events: thioacetal hydrolysis, hemiacetal re-
duction, oxidation of both primary and secondary alcohol, dou-
ble reductive amination and final global debenzylation.
One interesting though not fully explained observation we
made during our efforts to synthesize phenylthiodisaccharide
27 is that, when executing the glycosylation at –78 °C, the reac-
tion turned out to be unproductive. Instead of obtaining 27, no
less than 70 % of α-phenylthiogalactoside 31 (Scheme 6) was
obtained, with little to no formation of compound 27 observed.
Elevating the reaction temperature appeared to favor formation
of 27 over that of 31. At –20 °C, the product ration of 27:31
was 35:30, and as described above, at 0 °C compound 27 was
obtained as the exclusive isolated compound in good yield.
Although we have no satisfactory explanation for the tem-
perature dependence of this aglycon transfer (See Scheme 6),
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Scheme 6. Reagents and conditions: a) TMSOTf, CH2Cl2, –78 °C, 70 %.
there is literature precedence[13] for this phenomenon. This un-
desirable aglycon transfer is generally circumvented by the use
of bulky anomeric thiols or tuning of the protecting groups of
the acceptor, but these approaches require new synthetic
routes to the acceptor nucleophile. Although the reasons for
the shift in reaction outcome as a function of the reaction tem-
perature remain unclear at present it does represent a very ef-
fective means to circumvent the unproductive side reaction.
In conclusion, this work reports on the synthesis of five
glycosylated 1-deoxynojimycin derivatives. Four of these,
namely 6-O-(α-D-galactopyranosyl)-1-deoxynojirimycin (9), 4-O-
(α-D-glucopyranosyl)-1-deoxynojirimycin (14), 4-O-(-D-gluco-
pyranosyl)-1-deoxynojirimycin (19) and 4-O-(-D-galacto-
pyranosyl)-1-deoxynojirimycin (24) were synthesized from their
commercially available disaccharide (melibiose, maltose, cello-
biose and lactose, respectively) as precursor. As a further exam-
ple, 2-O-(α-galactopyranosyl)-1-deoxynojirimycin (Gal-DNJ, 29)
was also successfully synthesized via the same methodology
from its corresponding disaccharide, and the precursor disac-
charide for this transformation was synthesized via chemical
glycosylation. Thus the methodology presented appears gen-
eral and, though yields vary between the individual synthesis
schemes glycosylated DNJ derivatives can be prepared without
difficulties from their glycosylated glucose counterparts, as long
as the latter are synthetically tractable. One intrinsic shortcom-
ing of the presented procedure is the temporarily destruction
of the chiral center at C5 (glucopyranose numbering). Whereas
recovery in the presented examples of this chiral center during
reductive amination is excellent, such stereoselectivity may not
occur when starting from differently configured reducing sug-
ars. Thus the presented methodology will likely be less fruitful
when targeting disaccharidic iminosugars featuring, say, a
mannojirimycin or galactonojirimycin iminosugar. On the posi-
tive side, L-ido-configured iminosugar disaccharides should be
within easy reach by bismesylation of the diol in, for instance,
6 (Scheme 1), followed by nucleophilic displacement of both
mesylates with an amine. Such a strategy would again trans-
pose a route of synthesis that has been proven[6b] to be versa-
tile for the construction of non-glycosylated iminosugars to
tailored starting materials yielding glycosylated ones. Another
obvious extension would be to start, not from disaccharides,
but rather from oligosaccharides (for instance, cello/malto
oligosaccharides) and thus prepare larger oligosaccharides, the
reducing end sugar of which is substituted for DNJ.
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Experimental Section
General Methods: All solvents and reagents were obtained com-
mercially and used as received unless stated otherwise. Reactions
were executed at room temperature unless stated otherwise. Mois-
ture sensitive reactions were performed under argon atmosphere.
Water was removed from starting compounds by coevaporation
with toluene. Solvents were removed by evaporation under reduced
pressure. DCM, DMF, and THF were dried with activated 4 Å molec-
ular sieves for at least 12 hours before use. Compounds were visual-
ized during TLC analyses by UV (254 nm), and with the staining
solutions: aqueous solution of KMnO4 (5 g/L) and K2CO3 (25 g/L).
Visualization of hemi-acetals and glycosides was achieved by spray-
ing with a solution of 20 % H2SO4 in ethanol followed by charring
at ≈ 200 °C. Column chromatography was performed on silica gel
(40–63 μm). 1H NMR and 13C-APT NMR spectra were recorded on a
Bruker AV 400 (400/100 MHz) or Bruker 600 (600/150 MHz) spec-
trometer in CDCl3, MeOD or D2O. Chemical shifts are given in ppm
(δ) relative to TMS as internal standard (1H NMR in CDCl3) or the
signal of the deuterated solvent. Coupling constants (J) are given
in Hz. High resolution mass spectra were recorded by direct injec-
tion (2 μL of a 2 μM solution in water/acetonitrile/tert-butanol 1:1:1
v/v) on a mass spectrometer (Thermo Finnigan LTQ Orbitrap)
equipped with an electrospray ion source with resolution R = 60000
at m/z 400 (mass range m/z = 150–2000). IR spectra were recorded
on a Shimadzu FTIR-8300 and are reported in cm–1. Optical rota-
tions were measured on an automatic polarimeter of sodium D-line,
at λ = 589 nm. Size-exclusion purifications were performed on an
ÄKTA-explorer provided by GE-Healthcare polymer HW-40S from
Toyopearl, column size d = 26 mm; l = 60 mm, mobile phase
NH4HCO3 (0.15 M) in H2O, flow 1.5 mL/min. Purification on HPLC
were performed on a Prep LCMS, Gemini from Phenomenex B.V.
(C-18, 110 Å, 5 μm, 19 × 150 mm column).
1,2,3,4-Tetra-O-acetyl-6-O-(2,3,4,6-tetra-O-acetyl-α-D-galacto-
pyranosyl)--glucopyranose (2): A suspension of Ac2O (59.0 mL,
0.625 mol) and NaOAc (4.21 g, 51.3 mmol) were heated to reflux.
When refluxing began the heat source was removed and melibiose
(10.0 g, 29.2 mmol), which was co-evaporated with toluene (3 ×),
was added in small portions. The mixture was heated to reflux for 1
hour. TLC analysis confirmed complete consumption of the starting
material 1 (1:1, PE/EtOAc, RF = 0.39). The mixture was poured into
ice water (400 mL) which was vigorously stirred. DCM (150 mL) was
added and the layers were separated. The organic layer was washed
with cold water (150 mL), sat. aq. NaHCO3 solution (2 × 150 mL)
and brine (150 mL) and the organic layer was dried (Na2SO4), fil-
tered, and concentrated. The residue was purified with silica gel
column chromatography (2:1 → 1:1 → 1:2, PE/EtOAc) to give 2 in
90 % yield (17.8 g, 26.2 mmol). RF = 0.39 (1:1, PE/EtOAc). 1H NMR
(400 MHz, CDCl3): δ/ppm = 5.70 (d, J = 8.3 Hz, 1 H, H-1), 5.45 (d,
J = 2.9 Hz, 1 H, H-4′), 5.34 (dd, J = 10.8, 3.3 Hz, 1 H, H-3′), 5.27 (t,
J = 9.4 Hz, 1 H, H-4), 5.16 (m, 2 H, H-1′, H-4), 5.07 (m, 2 H, H-2,
H-3), 4.21 (dd, J = 11.4, 5.0 Hz, 1 H, H-5′), 4.15–4.02 (m, 3 H, H-2′,
H-6), 3.83 (ddd, J = 9.9, 3.9, 2.6 Hz, 1 H, H-5), 3.74 (dd, J = 11.7,
4.3 Hz, 1 H, H-6′a), 3.65 (dd, J = 11.8, 2.3 Hz, 1 H, H-6′b), 2.24–1.96
(m, 24 H, 8 × CH3). 13C NMR (100 MHz, CDCl3): δ/ppm = 170.7–169.1
(C=O), 96.5 (C-1′), 91.7 (C-1), 73.6 (C-5), 73.0 (C-4), 70.3 (C-3), 68.4
(C-4), 68.2 (C-4′), 68.1 (C-2), 67.6 (C-3′), 66.6 (C-5′), 65.8 (C-6), 61.9
(C-6′), 20.9–20.7 (8 × CH3).
2,3,4-Tri-O-acetyl-6-O-(2,3,4,6-tetra-O-acetyl-α-D-galactopyr-
anosyl)-1-thio-D-glucopyranose (3): PhSH (5.2 mL, 51.0 mmol)
was added to a stirred solution of 2 (17.8 g, 26.2 mmol) in dry
DCM (50 mL) and kept under argon atmosphere. After cooling the
solution to 0 °C, BF3·Et2O (4.9 mL, 39.7 mmol) was added dropwise,
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upon which the solution turned to orange. The mixture was stirred
for 4 hours at room temperature, after which TLC analysis showed
complete consumption of the starting material. DCM (50 mL) was
added to the reaction mixture and the solution was washed with
sat. aq. NaHCO3 (100 mL, 2 ×). The organic layer was dried (Na2SO4).
After filtration, concentration and evaporation of the volatiles, the
crude product was purified by silica gel column chromatography
(3:1 → 7:3 → 1:1, PE/EtOAc), to give 3 as a white solid product in
82 % yield (15.6 g, 21.4 mmol). RF = 0.43 (1:1, PE/EtOAc). 1H NMR
(400 MHz, CDCl3): δ/ppm = 7.45 (dd, J = 8.0, 1.4 Hz, 2 H, HAr SPh),
7.40–7.30 (m, 3 H, HAr SPh), 5.35 (dd, J = 3.5, 1.2 Hz, 1 H, H-4′), 5.32
(dd, J = 10.2, 3.4 Hz, 1 H, H-3′), 5.24 (t, J = 9.4 Hz, 1 H, H-3), 5.14 (d,
J = 3.7 Hz, 1 H, H-1′), 5.11 (dd, J = 10.2, 3.7 Hz, 1 H, H-2′), 5.03 (t,
J = 9.6 Hz, 1 H, H-4), 4.96 (dd, J = 10.1, 9.2 Hz, 1 H, H-2), 4.78 (d,
J = 10.1 Hz, 1 H, H-1), 4.21 (td, J = 6.6, 1.3 Hz, 1 H, H-5′), 4.03 (d,
J = 6.9 Hz, 2 H, H2-6′), 3.77 (dd, J = 10.6, 5.8 Hz, 1 H, H-6b), 3.71
(dd, J = 5.8, 2.0 Hz, 1 H, H-5), 3.56 (dd, J = 10.7, 1.9 Hz, 1 H, H-6a),
2.15–1.99 (m, 21 H, 7 × CH3). 13C NMR (100 MHz, CDCl3): δ/ppm =
170.6–169.4 (C=O), 132.2 (CAr Ph), 132.1 (Cq SPh), 129.3, 128.4 (CAr
SPh), 96.4 (C-1′), 85.7 (C-1), 76.8 (C-5), 74.1 (C-3), 70.1 (C-2), 68.8 (C-
4), 68.2 (C-2′), 68.2 (C-4′), 67.5 (C-3′), 66.9 (C-6), 66.6 (C-5), 61.8 (C-
6′), 21.0–20.7 (7 × CH3). [α]D20 = +73.3 (c = 1.14, CHCl3). IR: ν̃/cm–1 =
1750, 1734, 1373, 1218, 1037.
2,3,4-Tri-O-benzyl-6-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyr-
anosyl)-1-thio-D-glucopyranose (4): Compound 3 (15.0 g,
20.6 mmol) was co-evaporated with toluene (3 ×) and dissolved in
dry MeOH (100 mL). A catalytic amount of NaOMe was added and
the reaction mixture was stirred for two hours. TLC-MS analysis
showed complete conversion of the starting material into a more
polar product. The mixture was diluted with MeOH after which Am-
berlite H+ was added until the pH was adjusted to 7. After filtration
and concentration the thus obtained product (D-galactopyranosyl-
1-thio-D-glucopyranose) was co-evaporated with toluene (3 ×), dis-
solved in DMF (100 mL), and BnBr (20.9 mL, 176 mmol) was added.
The solution was cooled to 0 °C, and NaH (14.5 g, 360 mmol) was
added in small portions, after which the solution was stirred over-
night under argon atmosphere. TLC analysis showed complete con-
sumption of the starting compound (1:1, PE/EtOAc). After cooling
down to 0 °C, the reaction mixture was quenched with MeOH, after
which the volatiles were evaporated and EtOAc (200 mL) added.
The mixture was washed with HCl solution (1 M, 100 mL, 2 ×). After
being dried (Na2SO4), filtered, and concentrated, the crude product
was purified with silica gel column chromatography (17:3 → 4:1 →
1:1, PE/EtOAc) to give 4 in 50 % yield over the 2 steps (11.0 g,
10.3 mmol). RF = 0.88 (1:1, PE/EtOAc). 1H NMR (400 MHz, CDCl3):
δ/ppm = 7.54–7.12 (m, 40 H, HAr SPh/Bn), 5.03 (d, J = 3.5 Hz, 1 H,
H-1′), 4.66 (d, J = 9.9 Hz, 1 H, H-1), 4.97–4.37 (m, 14 H, 7 × CH2 Bn),
4.05 (dd, J = 9.7, 3.5 Hz, 1 H, H-2′), 3.99 (t, J = 6.5 Hz, 1 H, H-5), 3.89
(m, 1 H, H-3′), 3.86 (d, J = 2.9 Hz, 1 H, H-4′), 3.78 (qd, J = 11.7, 3.5 Hz,
2 H, H2-6′), 3.68–3.59 (m, 2 H, H-3, H-4), 3.54 (dd, J = 9.3, 5.9 Hz, 1
H, H-5′), 3.49 (dd, J = 9.5, 6.5 Hz, 2 H, H2-6), 3.26 (dd, J = 9.9, 8.5 Hz,
1 H, H-2). 13C NMR (100 MHz, CDCl3): δ/ppm = 139.0–138.1 (Cq Bn),
134.2 (Cq SPh), 131.9–127.5 (CAr Bn), 97.9 (C-1′), 87.8 (C-1), 86.8 (C-
3), 81.2 (C-2), 79.0 (C-5), 78.5 (C-4′), 78.0 (C-4), 76.9 (C-2), 75.8, 75.6
(2 × CH2 Bn), 75.3 (C-3′), 75.1, 74.9, 73.4, 73.2, 72.8 (5 × CH2 Bn),
72.8, 69.3 (C-5), 69.1 (C-6), 66.4 (C-6′). IR: ν̃/cm–1 = 3088, 3063, 3030,
2905, 2866, 1454, 1352, 1094, 1040.
2,3,4-Tri-O-benzyl-6-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyr-
anosyl)-α/-glucopyranose (5): NIS (22 mg, 97 μmol) and TFA
(30 μL, 0.39 μmol) were added to a cooled solution of 4 (94 mg,
88 μmol) in DCM (2 mL) at 0 °C. After an hour of stirring TLC analysis
(4:1, toluene/EtOAc) showed complete consumption of the starting
material. Sat. aq. Na2S2O3 (7 mL) followed by sat. aq. NaHCO3 (7 mL)
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were added. The mixture was diluted with DCM, and after 30 min-
utes of stirring the layers were separated. The organic layer was
dried (MgSO4) and after filtering and concentrating the crude prod-
uct was purified on silica gel column chromatography (9:1 → 7:3
→ 6:4, PE/EtOAc) to give 5 in 77 % yield (70 mg, 68 μmol). RF =
0.30 and 0.40 (7:3, PE/EtOAc). For the major anomer: 1H NMR
(400 MHz, CDCl3): δ/ppm = 7.41–7.19 (m, 35 H, HAr Bn), 5.09 (d, J =
3.6 Hz, 1 H, H-1′), 4.98 (d, J = 3.5 Hz, 1 H, H-1), 4.95–4.28 (m, 14 H,
7 × CH2 Bn), 4.13 (dt, J = 14.3, 6.8 Hz, 1 H, H-5′), 4.07–3.98 (m, 2 H,
H-4, H-5), 3.96–3.88 (m, 3 H, H-2′, H-3, H-4′), 3.85 (d, J = 11.7 Hz, 1
H, H-6′b), 3.72 (dd, J = 12.0, 5.5 Hz, 1 H, H-6′b), 3.64–3.43 (m, 3 H,
H-2, H-6), 3.39 (dd, J = 9.4, 3.5 Hz, 1 H, H-2), 3.26 (dd, J = 8.6, 7.3 Hz,
1 H, H-3′). 13C NMR (100 MHz, CDCl3): δ/ppm = 138.9, 138.8, 138.4,
138.3, 138.1, 137.9, 137.8 (7 × Cq Bn), 128.6–127.6 (CAr Bn), 98.5
(C-1′), 91.1 (C-1), 83.6 (C-3′), 81.9 (C-3), 80.4 (C-4), 78.6 (C-2), 78.2 (C-
2′), 76.7 (C-4′), 75.8–72.7 (7 × CH2 Bn), 70.8 (C-5′), 69.6 (C-5), 69.6
(C-6), 67.8 (C-6′). [α]D20 = +38.1 (c = 1.03, CHCl3). IR: ν̃/cm–1 = 3030,
2920, 2868, 2247, 1497, 1454, 1357, 1090, 1026. HRMS: found
995.4343 [C61H64O11 + Na]+, calculated for [C61H64O11 + Na]+
995.4341.
2,3,4-Tri-O-benzyl-6-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyr-
anosyl)-D-glucitol (6): LiAlH4 in THF (6.0 mL, 2 M, 12.0 mmol) was
slowly added to a cooled (0 °C) solution of 5 (3.91 g, 4.02 mmol,
co-evaporated 3 × with toluene), in dry THF (40 mL) under argon
atmosphere. The mixture was stirred overnight allowing the tem-
perature to reach room temperature TLC analysis showed absent of
the starting compound (7:3, PE/EtOAc). The mixture was cooled in
an ice-bath, after which it was slowly quenched with H2O. Then
NaOH solution (3 M, 40 mL) was added followed by celite. The solu-
tion was stirred until a homogeneous mixture was formed after
which it was filtered and the filter cake rinsed with Et2O. H2O
(50 mL) and EtOAc (50 mL) was added and the organic layer was
dried (Na2SO4), filtered and concentrated, after which the residue
was purified by silica gel column chromatography (4:1 → 7:3 → 3:2,
PE/EtOAc) to give 6 as a yellow oil in 74 % yield (2.88 g, 2.95 mmol).
RF = 0.22 (7:3, PE/EtOAc). 1H NMR (400 MHz, CDCl3): δ/ppm = 7.41–
7.19 (m, 35 H, HAr Bn), 4.88 (d, J = 3.7 Hz, 1 H, H-1′), 5.03–4.29 (m,
14 H, CH2 Bn), 4.06 (dd, J = 10.0, 3.6 Hz, 1 H, H-2′), 4.02–3.93 (m, 3
H, H-4′, H-5, H-5′), 3.92–3.86 (m, 2 H, H-3, H-3′), 3.82 (dd, J = 11.1,
5.3 Hz, 1 H, H-6a), 3.78–3.68 (m, 4 H, H-4, H-1a, H-2, H-4, H-6b), 3.55
(dd, J = 11.3, 4.3 Hz, 1 H, H-1b), 3.49 (d, J = 6.5 Hz, 2 H, H-6′). 13C
NMR (100 MHz, CDCl3): δ/ppm = 138.7–138.0 (Cq Bn), 128.6–127.5
(CAr Bn), 99.0 (C-1′), 79.6 (C-3), 79.4 (C-4), 79.2 (C-2), 78.5 (C-3′), 76.5
(C-2′), 74.9, 74.9 (2 × CH2 Bn), 74.8 (C-4′), 73.9–72.9 (5 × CH2 Bn),
70.6 (C-6), 70.4 (C-5′), 69.8 (C-5), 69.0 (C-6′), 61.9 (C-1). [α]D20 = +34.4
(c = 1.02, CHCl3). IR: ν̃/cm–1 = 3335, 2974, 2289, 1636, 1456, 1418,
1088, 1045. HRMS: found 997.4491 [C61H64O11 + Na]+, calculated for
[C61H64O11 + Na]+ 997.4497.
2,3,4-Tri-O-benzyl-6-O-(2,3,4,6-tetra-α-D-galactopyranosyl)-1-
deoxynojirimycin (8): A solution of (COCl)2 (1.2 mL, 14.0 mmol) in
dry DCM (15 mL) under argon atmosphere, was cooled to –78 °C.
DMSO (1.2 mL, 16.9 mmol) dissolved in dry DCM (12 mL) was added
dropwise. After 40 min, 7 (4.28 g, 3.22 mmol, co-evaporated 3 ×
with toluene), in dry DCM (18 mL), was added dropwise to the
mixture. The reaction was stirred for 2 h at –70 °C, after which Et3N
(5.4 mL, 38.7 mmol) was added dropwise. The mixture was gradu-
ally warmed to –5 °C after which it was poured into a cooled (0 °C)
MeOH solution (200 mL) containing NaCNBH3 (0.81 g, 12.3 mmol),
HCOONH4 (4.07 g, 64.5 mmol), and Na2SO4 (1.37 g, 9.67 mmol). The
mixture was stirred overnight allowing the reaction to reach room
temperature. TLC analysis showed the formation of the product.
After filtering, the solvents were evaporated, after which the residue
was dissolved in EtOAc (200 mL). The solution was washed with sat.
Full Paper
aq. NaHCO3 (200 mL). The organic layer was dried (Na2SO4), filtered
and concentrated, and the crude product was purified with silica
gel column chromatography (4:1 → 7:3 → 3:2 → 1:1, PE/EtOAc) to
give the 8 in 71 % yield (2.17 g, 2.27 mmol). RF = 0.4 (1:1, PE/EtOAc).
1H NMR (400 MHz, CDCl3): δ/ppm = 7.45–7.16 (m, 35 H, HAr Bn),
4.91 (d, J = 3.7 Hz, 1 H, H-1′), 5.05–4.26 (m, 14 H, 7 × CH2 Bn), 4.06
(dd, J = 10.0, 3.6 Hz, 1 H, H-2′), 3.97 (d, J = 2.7 Hz, 1 H, H-4′), 3.98–
3.93 (m, 2 H, H-3′, H-5′), 3.86 (dd, J = 10.5, 5.3 Hz, 1 H, H-6a), 3.64
(dd, J = 10.5, 2.6 Hz, 1 H, H-6b), 3.54 (dd, J = 9.1, 2.5 Hz, 1 H,
H-6′a), 3.53 (t, J = 9.0 Hz, 1 H, H-3), 3.49 (dd, J = 9.3, 6.1 Hz, 1 H, H-
6′b), 3.32 (t, J = 9.2 Hz, 1 H, H-2), 3.31 (t, J = 9.5, 1 H, H-4), 2.95 (dd,
J = 12.5, 5.1, 1 H, H-1′a), 2.68 (ddd, J = 9.6, 5.2, 2.6, 1 H, H-5), 2.37
(dd, J = 12.4, 10.7, 1 H, H-1′b). 13C NMR (100 MHz, CDCl3): δ/ppm =
138.8–137.9 (Cq Bn), 128.4–127.4 (CAr Bn), 99.0 (C-1′), 87.2 (C-3), 80.9
(C-4), 80.0 (C-2), 78.8 (C-3′), 76.8 (C-2′), 75.6, 75.1, 74.7 (3 × CH2 Bn),
74.7 (C-4′), 73.6, 73.4, 72.6, 72.6 (4 × CH2 Bn), 69.6 (C-5′), 69.4 (C-6),
68.8 (C-6′), 59.5 (C-5), 47.7 (C-1). IR: ν̃/cm–1 = 3032, 2899, 2872, 1497,
1453, 1354, 1208, 1093, 1059, 1027. [α]D20 = +58.2 (c = 0.5, CHCl3).
HRMS: found 956.4736 [C61H66NO9 + H]+, calculated for [C61H66NO9
+ H]+ 956.4732.
6-O-(α-D-Galactopyranosyl)-1-deoxynojirimycin (9): A mixture of
DMF/MeOH (1:1, 20 mL), HCl (2 mL, 1 M) and 8 (2.00 g, 2.09 mmol)
was flushed with argon (3 ×). Then a catalytic amount of Pd/C
(20 %) was added, after which H2 was flushed through the mixture,
letting the solution shake overnight under H2 atmosphere (4 bar).
HPLC analysis showed complete conversion of starting material into
desired product. Then the catalyst was filtered and the solution
was concentrated. The crude product was purified on size-exclusion
column (NH4HCO3 in water 0.15 M). After co-evaporating (3 ×) with
MilliQ water, product 9 was obtained as a white solid in 75 % yield
(326 mg, 1.00 mmol). 1H NMR (400 MHz, MeOD): δ/ppm = 4.84 (d,
J = 3.4 Hz, 1 H, H-1′), 4.01 (dd, J = 10.5, 4.7 Hz, 1 H, H-6a), 3.90 (dd,
J = 3.0, 1.2 Hz, 1 H, H-4′), 3.84 (td, J = 6.1, 1.1 Hz, 1 H, H-5′), 3.80
(dd, J = 10.1, 3.4 Hz, 1 H, H-2′), 3.76 (dd, J = 10.1, 3.0 Hz, 1 H,
H-3′), 3.70 (d, J = 6.1 Hz, 2 H, H-6′), 3.59 (dd, J = 10.4, 2.5 Hz, 1 H,
H-6b), 3.52 (ddd, J = 11.0, 9.1, 5.1 Hz, 1 H, H-2), 3.38 (dd, J = 10.1,
9.0, 1 H, H-4), 3.25 (t, J = 9.0 Hz, 1 H, H-3), 3.20 (dd, J = 12.3, 5.1 Hz,
1 H, H-1a), 2.82 (ddd, J = 10.0, 4.6, 2.6 Hz, 1 H, H-5), 2.60 (dd, J =
12.3, 11.0 Hz, 1 H, H-1b). 13C NMR (100 MHz, MeOD): δ/ppm = 100.3
(C-1′), 79.9 (C-3), 72.4 (C-5′), 71.6 (C-4), 71.5 (C-2), 71.2 (C-3), 70.9
(C-4′), 70.4 (C-2′), 66.8 (C-6), 62.6 (C-6′), 60.5 (C-5), 49.9 (C-1). [α]D20 =
+92.8 (c = 1.0, MeOH). IR: ν̃/cm–1 = 3482, 2928, 2962, 1653, 1506,
1409, 1437, 1387, 1255, 1092, 1063. HRMS: found 326.1446
[C12H23NO9M + H]+, calculated for [C12H23NO9 + H]+ 326.1446.
1,2,3,6-Tetra-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-α-D-gluco-
pyranosyl)--glucopyranose (11): A suspension of Ac2O (59.0 mL,
0.625 mol) and NaOAc (4.33 g, 52.8 mmol) were heated to reflux.
When refluxing began the heat source was removed and maltose
(9.94 g, 29.0 mmol, co-evaporated with 3 × toluene) was added in
small portions. The mixture was heated again to reflux and after an
hour, TLC analysis confirmed the formation of the product (1:1, PE/
EtOAc, RF = 0.36). The mixture was poured into ice water (400 mL)
and vigorously stirred. DCM (150 mL) was added and the layers
were separated after which the organic layer was washed with wa-
ter (200 mL), sat. aq. NaHCO3 solution (2 × 150 mL) and brine
(200 mL). After the organic layer was dried (Na2SO4), filtered, and
concentrated, the residue was purified by silica gel column chroma-
tography (1:1 → 1:2 → 0:1, PE/EtOAc) to give pure 11 in 94 % yield
(18.5 g, 27.3 mmol). 1H NMR (400 MHz, CDCl3): δ/ppm = 5.74 (d, J =
8.2 Hz, 1 H, H-1), 5.42 (dd, J = 12.4, 4.0 Hz, 1 H, H-1′), 5.36 (dd, J =
9.8, 2.3 Hz, 1 H, H-3), 5.33–5.26 (m, 1 H, H-3′), 5.11–4.94 (m, 2 H, H-
4′, H-2), 4.86 (ddd, J = 10.5, 6.2, 4.0 Hz, 1 H, H-2′), 4.45 (dd, J = 12.3,
2.4 Hz, 1 H, H-6′a), 4.27–4.19 (m, 2 H, H-6a, H-6′b), 4.14–4.08 (m, 1
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H, H-6b), 4.04 (ddd, J = 8.9, 5.8, 3.8 Hz, 1 H, H-4), 3.96–3.91 (m, 1 H,
H-5′), 3.84 (ddd, J = 9.6, 4.3, 2.5 Hz, 1 H, H-5), 2.26–1.96 (m, 24 H,
8 × CH3). 13C NMR (100 MHz, CDCl3): δ/ppm = 170.6–168.9 (8 ×
C=O), 95.8 (C-1′), 91.3 (C-1), 75.3 (C-3′), 73.0 (C-5), 72.4 (C-4), 71.0
(C-2), 70.1 (C-2′), 69.3 (C-3), 68.6 (C-5′), 68.0 (C-4′), 62.6 (C-6′), 61.5
(C-6), 20.9–20.6 (8 × CH3).
2,3,6-Tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl-α-D-glucopyran-
osyl)-α/-glucopyranose (12): Step 1: According to the procedure
described for the preparation for compound 3, 1,2,3,6-tetra-O-
acetyl-4-O-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)--glucopyr-
anose (12.1 g, 16.5 mmol, 61 % yield) was synthesized from 11
(18.5 g, 27.3 mmol) as a colorless oil. RF = 0.43 (1:1, PE/EtOAc). 1H
NMR (400 MHz, CDCl3): δ/ppm = 7.51–7.44 (m, 2 H, HAr SPh), 7.36–
7.28 (m, 3 H, HAr SPh), 5.39 (d, J = 4.0 Hz, 1 H, H-1′), 5.34 (dd, J =
10.5, 9.6 Hz, 1 H, H-3), 5.28 (t, J = 8.9 Hz, 1 H, H-3′), 5.04 (t, J =
9.9 Hz, 1 H, H-4′), 4.85 (dd, J = 10.5, 4.0 Hz, 1 H, H-2′), 4.79 (d, J =
9.0 Hz, 1 H, H-2), 4.73 (d, J = 10.1 Hz, 1 H, H-1), 4.54 (dd, J = 12.1,
2.5 Hz, 1 H, H-6′a), 4.24 (dd, J = 10.5, 4.5 Hz, 1 H, H-6a), 4.21 (dd,
J = 10.2, 4.4 Hz, 1 H, H-6′b), 4.04 (dd, J = 10.2, 4.4 Hz, 1 H, H-6b),
3.95 (dd, J = 9.7, 9.0 Hz, 1 H, H-4), 3.94 (ddd, J = 10.4, 4.0, 2.4 Hz, 1
H, H-5′), 3.72 (ddd, J = 9.8, 4.8, 2.6 Hz, 1 H, H-5), 2.14–1.99 (m, 21
H, 7 × CH3). 13C NMR (100 MHz, CDCl3): δ/ppm = 170.7–169.6 (C=
O), 133.5 (CAr SPh), 131.4 (Cq SPh), 129.0, 128.6 (CAr SPh), 95.7 (C-1′
), 85.2 (C-1), 76.6 (C-3′), 76.2 (C-5), 72.5 (C-4), 70.8 (C-2), 70.1 (C-2′),
69.4 (C-3), 68.6 (C-5′), 68.1 (C-4′), 62.9 (C-6′), 61.6 (C-6), 21.1–20.7
(7 × CH3). [α]D20 = +30.6 (c = 1.0, CHCl3). IR: ν̃/cm–1 = 1746, 1368,
1223, 1038, 912. Step 2: According to the procedure described for
the preparation for compound 4, 2,3,6-tri-O-acetyl-4-O-(2,3,4,6-
tetra-O-acetyl-α-D-glucopyranosyl)-1-thio-D-glucopyranose (15.4 g,
14.5 mmol, 89 % yield) was synthesized from the above mentioned
acetyl phenylthiomaltoside (11.9 g, 13.3 mmol) as a light yellow oil.
RF = 0.63 (4:1, PE/EtOAc). 1H NMR (400 MHz, CDCl3): δ/ppm = 7.60
(dd, J = 6.5, 3.0 Hz, 2 H, HAr SPh), 7.33–7.16 (m, 32 H, HAr Bn, HAr
SPh), 7.13–7.08 (m, 6 H, HAr Bn), 5.64 (d, J = 3.6 Hz, 1 H, H-1′), 4.92–
4.76 (m, 6 H, 3 × CH2 Bn), 4.70 (d, J = 9.7 Hz, 1 H, H-1), 4.62–4.41
(m, 7 H, 7 × CHHBn), 4.31 (d, J = 12.1 Hz, 1 H, CHHBn), 4.12 (t, J =
9.2 Hz, 1 H, H-4), 3.93 (dd, J = 9.9, 8.9 Hz, 1 H, H-3′), 3.89 (dd, J =
11.3, 4.3 Hz, 1 H, H-6′a), 3.83 (dd, J = 6.5, 4.3 Hz, 1 H, H-6′b), 3.82
(t, J = 8.8 Hz, 1 H, H-3), 3.79 (dd, J = 7.3, 2.7 Hz, 1 H, H-5′), 3.67 (dd,
J = 17.1, 8.0 Hz, 1 H, H-4′), 3.60 (dd, J = 11.2, 1.8 Hz, 1 H, H-6a), 3.59
(dd, J = 10.5, 3.3 Hz, 1 H, H-5), 3.58 (t, J = 10.2 Hz, 1 H, H-2), 3.51
(dd, J = 9.9, 3.7 Hz, 1 H, H-2′), 3.45 (dd, J = 10.6, 1.8 Hz, 1 H, H-6b).
13C NMR (100 MHz, CDCl3): δ/ppm = 138.7–137.8 (7 × Cq Bn), 133.7
(Cq SPh), 132.0–126.5 (CAr SPh), 97.1 (C-1′), 87.2 (C-1), 86.7 (C-3), 82.0
(C-3′), 80.9 (C-2), 79.4 (C-2′), 78.8 (C-5), 77.7 (C-4′), 75.5–73.3 (7 ×
CH2Bn), 72.7 (C-4), 71.1 (C-5′), 69.2 (C-6′), 68.3 (C-6). [α]D20 = +2.87
(c = 2.31, CHCl3). IR: ν̃/cm–1 = 3063, 3030, 2904, 2864, 1452, 1360,
1207, 1140, 1084, 1055, 1026. Step 3: Compound 12 (12.3 g,
12.3 mmol, 93 % yield) was synthesized from 2,3,6-tri-O-acetyl-4-O-
(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)-1-thio-d-glucopyranose
(14.5 g, 13.6 mmol) according to the procedure described for the
preparation for compound 5, as a light yellow oil. RF = 0.40 and 0.30
(7:3, PE/EtOAc). For the major anomer: 1H NMR (400 MHz, CDCl3):
δ/ppm = 7.31–7.07 (m, 35 H, HAr Bn), 5.66 (dd, J = 8.6, 3.6 Hz, 1 H,
H-1′), 5.21 (t, J = 2.9 Hz, 1 H, H-1), 5.02–4.26 (m, 14 H, 7 × CH2 Bn),
4.31 (dd, J = 12.2, 10.0 Hz, 1 H, H-4), 4.13 (t, J = 8.8 Hz, 1 H, H-3),
4.03–3.82 (m, 2 H, H-3′, H-5), 3.80–3.58 (m, 5 H, H-2, H-4′, H-5′, H2-
6′), 3.55–3.45 (m, 2 H, H-2′, H-6a), 3.39 (ddd, J = 10.7, 3.6, 1.7 Hz, 1
H, H-6b). 13C NMR (100 MHz, CDCl3): δ/ppm = 138.9, 138.7, 138.4,
138.2, 138.0, 137.9, 137.7 (7 × Cq Bn), 128.4 127.1 (CAr Bn),
96.9 (C-1′), 90.7 (C-1), 82.0 (C-3′), 81.4 (C-4), 80.0 (C-2), 79.4 (C-2′),
77.7 (C-4′), 75.6–72.9 (7 × CH2 Bn), 72.9 (C-3), 71.1 (C-5), 69.6 (C-5′),
69.2 (C-6′), 68.1 (C-6). [α]D20 = +32.8 (c = 1.0, CHCl3). IR: ν̃/cm–1 =
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3418, 3063, 3030, 2903, 2864, 1497, 1452, 1362, 1265, 1207, 1146,
1088, 1043, 1026.
4-O-(α-D-Glucopyranosyl)-1-deoxynojirimycin (14): Step 1: Ac-
cording to the procedure described for the preparation for com-
pound 6, 2,3,6-Tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl-α-D-gluco-
pyranosyl)-D-glucitol (8.33 g, 8.55 mmol, 74 % yield) was synthe-
sized from 12 (11.25 g, 11.57 mmol) as a light yellow oil. RF = 0.31
(7:3, PE/EtOAc). 1H NMR (400 MHz, CDCl3): δ/ppm = 7.36–7.07 (m,
35 H, HAr Bn), 4.82 (d, J = 3.1 Hz, 1 H, H-1′), 4.96–4.35 (m, 14 H, 7 ×
CH2 Bn), 4.12 (dd, J = 8.6, 4.0 Hz, 1 H, H-3′), 3.98 (ddd, J = 10.2, 3.2,
2.1 Hz, 1 H, H-5), 3.96–3.90 (m, 4 H, H-5′, H-4, H-3′, H-4′), 3.78–3.64
(m, 2 H, H2-1), 3.60–3.53 (m, 6 H, H2-6, H2-6′, H-2, H-2′). 13C NMR
(100 MHz, CDCl3): δ/ppm = 138.2–137.6 (Cq Bn), 129.1–125.4 (CAr
Bn), 99.2 (C-1′), 82.0 (C-3), 79.9 (C-3′), 79.7 (C-4′), 79.4 (C-2), 78.8
(C-4), 77.8 (C-2′), 75.7–72.8 (7 × CH2 Bn), 71.8 (C-3′), 71.6 (C-6), 71.2
(C-5), 68.3 (C-6′), 61.6 (C-1). [α]D20 = +38.1 (c = 1.03, CHCl3). IR:
ν̃/cm–1 = 3420, 3063, 3030, 2862, 1454, 1207, 1086, 1070, 1028.
HRMS: found 997.4497 [C61H64O11 + H]+, calculated for [C61H64O11
+ Na]+ 997.4497. Step 2: According to the procedure described
for the preparation for compound 8, 2,3,6-tri-O-benzyl-4-O-(2,3,4,6-
tetra-O-benzyl-α-D-glucopyranosyl)-1-deoxynojirimycin (0.428 g,
0.448 mmol, 44 % yield) was synthesized from 2,3,6-tri-O-benzyl-4-
O-(2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyl)-D-glucitol (0.998 g,
1.02 mmol) as a light yellow oil. RF = 0.38 (1:1, PE/EtOAc). 1H NMR
(400 MHz, CDCl3): δ/ppm = 7.49–7.26 (m, 35 H, HAr Bn), 5.94 (d, J =
3.6 Hz, 1 H, H-1′), 5.30–4.46 (m, 14 H, 7 × CH2 Bn), 4.11 (dd, J = 9.8,
8.5 Hz, 1 H, H-3′), 3.98 (dd, J = 9.5, 8.7 Hz, 1 H, H-4), 3.93–3.87 (m,
2 H, H-5′, H-6a), 3.88 (t, J = 8.7 Hz, 1 H, H-3), 3.84 (dd, J = 8.7, 1.3 Hz,
1 H, H-4′), 3.81 (dd, J = 8.7, 5.6 Hz, 1 H, H-6b), 3.73 (dd, J = 10.6,
2.8 Hz, 1 H, H-6′a), 3.73–3.70 (m, 1 H, H-2), 3.67 (dd, J = 9.8, 3.6 Hz,
1 H, H-2′), 3.61 (dd, J = 10.4, 1.3 Hz, 1 H, H-6′b), 3.42 (dd, J = 12.3,
5.1 Hz, 1 H, H-1a), 3.03 (ddd, J = 9.1, 5.8, 2.9, 1 H, H-5), 2.70 (dd, J =
12.3, 10.6 Hz, 1 H, H-1b). 13C NMR (100 MHz, CDCl3): δ/ppm = 139.1–
137.9 (7 × Cq Bn), 128.3–126.5 (CAr Bn), 96.6 (C-1′), 87.0 (C-3), 82.0
(C-3′), 80.9 (C-2), 79.3 (C-2′), 77.7 (C-4′), 75.5, 74.9 (2 × CH2 Bn), 74.2
(C-4), 73.8–72.5 (5 × CH2 Bn), 71.0 (C-5′), 70.5 (C-6), 68.1 (C-6′), 59.0
(C-5), 47.8 (C-1). [α]D20 = +26.0 (c = 0.7, CHCl3). IR: ν̃/cm–1 = 2918,
2866, 1454, 1362, 1240, 1090, 1072, 1047, 1026. HRMS: found
956.4731 [C61H66NO9 + H]+, calculated for [C61H66NO9 + H]+
956.4732. Step 3: Compound 14 (0.24 g, 0.74 mmol, 71 % yield)
was synthesized from 2,3,6-tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl-
α-D-glucopyranosyl)-1-deoxynojirimycin (1.00 g, 1.04 mmol) accord-
ing to the procedure described for the preparation for compound
9, as a light yellow oil. 1H NMR (400 MHz, MeOD): δ/ppm = 5.21 (d,
J = 3.7 Hz, 1 H, H-1′), 4.00 (dd, J = 12.1, 4.8 Hz, 1 H, H-6a), 3.91 (dd,
J = 12.0, 3.0 Hz, 1 H, H-6b), 3.88–3.83 (m, 1 H, H-6′a), 3.77 (ddd, J =
4.8, 8.9, 10.8 Hz, 1 H, H-2). 3.81–3.66 (m, 4 H, H-3′, H-4′, H-6′b, H-3),
3.62 (dd, J = 9.7, 9.0 Hz, 1 H, H-4) 3.49 (dd, J = 9.7, 3.8 Hz, 1 H, H-
2′), 3.35 (dd, J = 12.5, 5.0 Hz, 1 H, H-1a), 3.30–3.23 (m, 2 H, H-5′, H-
5), 2.91 (dd, J = 12.4, 10.9 Hz, 1 H, H-1b). 13C NMR (100 MHz, MeOD):
δ/ppm = 103.1 (C-1′), 79.3 (C-3′), 77.7 (C-3), 75.1 (C-4′), 74.9 (C-4),
73.9 (C-2′), 71.4 (C-5′), 68.2 (C-2), 62.7 (C-6), 60.5 (C-5), 58.8 (C-6),
47.1 (C-1). [α]D20 = +25.0 (c = 0.2, MeOH). IR: ν̃/cm–1 = 3303, 2967,
1636, 1560, 1203, 1161, 1022. HRMS: found 326.1446 [C12H23NO9 +
H]+, calculated for [C12H23NO9 + H]+ 326.1446.
2,3,6-Tri-O-benzyl-4-(2′,3′,4′,6′-tetra-O-benzyl--D-galactopyr-
anosyl)-α/-D-glucopyranose (17): Step 1: According to the pro-
cedure described for the preparation for compound 4, 2,3,6-tri-O-
benzyl-4-(2′,3′,4′,6′-tetra-O-benzyl--D-galactopyranosyl)-1-thio-D-
glucopyranose (5.32 g, 5.00 mmol, 100 % yield) was synthesized
from lactose (3.64 g, 5.00 mmol) as a light yellow oil. RF = 0.67 (4:1,
PE/EtOAc). 1H NMR (400 MHz, CDCl3): δ/ppm = 7.61–7.04 (m, 40 H,
HAr Bn/SPh), 4.67 (d, J = 10.5 Hz, 1 H, H-1), 5.13–4.20 (m, 14 H, CH2
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Bn), 4.45 (d, J = 7.7 Hz, 1 H, H-1′), 4.00–3.91 (m, 2 H, H-4′, H-5′), 3.82
(dd, J = 11.0, 4.3 Hz, 1 H, H-6′a), 3.79–3.73 (m, 2 H, H-2′, H-6′b), 3.61
(t, J = 8.9 Hz, 1 H, H-3′), 3.52 (t, J = 7.6 Hz, 1 H, H-6a), 3.47–3.31 (m,
5 H, H-2, H-3, H-4, H-5 H-6b). 13C NMR (100 MHz, CDCl3): δ/ppm =
139.2–138.2 (7 × Cq Bn), 133.8 (Cq SPh), 132.2–127.3 (CAr Bn/SPh),
103.0 (C-1′), 87.5 (C-1), 85.1 (C-3′), 82.7 (C-4), 80.2 (C-2), 80.1 (C-2′),
79.5 (C-3), 76.6 (C-4′), 75.7, 75.6, 75.5, 74.5 (4 × CH2 Bn), 73.7 (C-5′),
73.5, 73.2 (2 × CH2 Bn), 73.1 (C-5), 72.2 (CH2 Bn), 68.5 (C-6′), 68.2 (C-
6). IR: ν̃/cm–1 = 3030, 2920, 2862, 1497, 1454, 1362, 1209, 1088,
1076, 1028, 1001. Step 2: Compound 17 (96.0 mg, 98.7 μmol, 85 %
yield) was synthesized from 2,3,6-tri-O-benzyl-4-(2′,3′,4′,6′-tetra-
O-benzyl--D-galactopyranosyl)-1-thio-D-glucopyranose (0.12 g,
0.12 mmol) according to the procedure described for the prepara-
tion for compound 5, as a light yellow oil. 1H NMR (400 MHz, CDCl3):
δ/ppm = 7.61–7.04 (m, 40 H, HAr Bn/SPh), 5.16 (d, J = 3.7 Hz, 1 H,
H-1), 5.10–4.17 (m, 14 H, CH2 Bn), 4.33 (d, J = 9.4 Hz, 1 H, H-1′),
3.99–3.87 (m, 3 H, H-2′, H-3′, H-5′), 3.87–3.80 (m, 2 H, H-4, H-3), 3.74
(ddd, J = 10.0, 7.5, 2.4 Hz, 1 H, H-6′a), 3.65 (dd, J = 10.5, 1.6 Hz, 1
H, H-6′b), 3.52 (ddd, J = 12.7, 9.3, 6.7 Hz, 2 H, H-2, H-6a), 3.42–3.29
(m, 4 H, H-3, H-4′, H-5, H-6b). 13C NMR (100 MHz, CDCl3): δ/ppm =
139.3–138.1 (Cq Bn), 128.5–127.2 (CAr Bn), 103.0 (C-1′), 91.5 (C-1),
82.5 (C-3), 80.0 (C-2), 79.2 (C-2′), 76.6 (C-3′), 75.5, 72.3 (2 × CH2 Bn),
75.1 (C-4′), 74.8 (CH2 Bn), 73.8 (C-4), 73.7, 73.6, 73.2 (3 × CH2 Bn),
73.2 (C-5′), 72.7 (CH2 Bn), 70.5 (C-5), 68.3 (C-6′), 68.1 (C-6). [α]D20 =
+12.4 (c = 1.07, CHCl3). IR: ν̃/cm–1 = 2920, 2864, 1452, 1396, 1362,
1207, 1090. HRMS: found 995.4342 [C61H64O11 + Na]+, calculated for
[C61H64O11 + Na]+ 995.4341.
4-(-D-Galactopyranosyl)-1-deoxynojirimycin (19): Step 1: Ac-
cording to the procedure described for the preparation for com-
pound 6, 2,3,6-tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl--D-galacto-
pyranosyl)-D-glucitol (4.17 g, 4.28 mmol, 77 % yield) was synthe-
sized from 17 (5.44 g, 5.59 mmol) as a light yellow oil. RF = 0.20
(7:3, PE/EtOAc). 1H NMR (400 MHz, CDCl3): δ/ppm = 7.36–7.18 (m,
35 H, HAr Bn), 4.97–4.22 (m, 14 H, 7 × CH2 Bn), 4.34 (dd, J = 7.2,
5.4 Hz, 1 H, H-1′), 4.03 (dd, J = 7.4, 2.4 Hz, 1 H, H-4), 3.99 (dt, J =
7.9, 3.8 Hz, 2 H, H-2, H-5′), 3.95 (dd, J = 7.8, 2.4 Hz, 1 H, H-3), 3.83
(d, J = 2.9 Hz, 1 H, H-4′), 3.77 (dd, J = 9.8, 7.7 Hz, 1 H, H-2′), 3.71
(dd, J = 6.9, 3.7, 2 H, H2-1), 3.66 (dd, J = 9.9, 4.4 Hz, 1 H, H-6′a), 3.55
(dd, J = 9.8, 3.0 Hz, 1 H, H-6′b), 3.48 (dd, J = 6.3, 2.5 Hz, 2 H, H2-6),
3.42 (dd, J = 10.0, 6.4 Hz, 1 H, H-5), 3.40 (dd, J = 9.7, 3.0 Hz, 1 H, H-
3′). 13C NMR (100 MHz, CDCl3): δ/ppm = 138.8–137.7 (Cq Bn), 128.5
(CAr Bn), 103.8 (C-1′), 82.42 (C-3′), 79.9 (C-4), 79.8 (C-2), 79.4 (C-2′),
77.5 (C-3), 75.4, 74.9, 74.7 (3 × CH2 Bn), 73.8 (C-4′), 73.6, 73.3 (2 ×
CH2 Bn), 73.3 (C-5), 73.2, 73.0 (2 × CH2 Bn), 70.8 (C-5′), 70.8 (C-6′),
68.9 (C-6), 62.3 (C-1). IR: ν̃/cm–1 = 3028, 2922, 2864, 1063, 1026,
1001. [α]D20 = +6.6 (c = 1.0, CHCl3). HRMS: found 997.4498 [C61H66O11
+ Na]+, calculated for [C61H66O11 + Na]+ 997.4497. Step 2: Accord-
ing to the procedure described for the preparation for compound
8, 2,3,6-tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl--D-galactopyranos-
yl)-1-deoxynojirimycin (0.90 g, 0.94 mmol, % yield) was synthesized
from 2,3,6-tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl--D-galactopyr-
anosyl)-D-glucitol (4.17 g, 4.28 mmol) as a light yellow oil. 1H NMR
(400 MHz, CDCl3): δ/ppm = 7.45–7.09 (m, 35 H, HAr Bn), 4.95 (d, J =
11.6 Hz, 1 H CHH Bn), 4.83 (d, J = 11.6 Hz, 2 H, CH2 Bn), 4.85 (d, J =
11.4 Hz, 1 H, CHH Bn), 4.75 (d, J = 11.9 Hz, 1 H, CHH Bn), 4.71 (d,
J = 11.6 Hz, 2 H, CH2 Bn), 4.67 (d, J = 11.5 Hz, 1 H, CHH Bn), 4.57
(d, J = 11.7 Hz, 1 H, CHH Bn), 4.44 (d, J = 11.7 Hz, 1 H, CH2 Bn), 4.38
(d, J = 11.8 Hz, 1 H, CHH Bn), 4.35 (d, J = 11.7 Hz, 1 H, CHH Bn),
4.34 (d, J = 7.7 Hz, 1 H, H-1′), 4.30 (d, J = 11.9 Hz, 1 H, CHH Bn),
4.05 (dd, J = 7.8, 2.4 Hz, 1 H, H-4), 4.01 (dd, J = 7.6, 3.7 Hz, 1 H, H-
5′), 4.00 (d, J = 3.4 Hz, 1 H, H-2),3.96 (dd, J = 7.8, 2.4 Hz, 1 H, H-3),
3.85 (d, J = 2.9 Hz, 1 H, H-4′), 3.79 (dd, J = 9.7, 7.7 Hz, 1 H, H-2′),
3.73 (dd, J = 8.6, 3.4 Hz, 2 H, H2-1), 3.68 (dd, J = 10.0, 4.2 Hz, 1 H,
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H-6′a), 3.57 (dd, J = 9.8, 3.0 Hz, 1 H, H-6′b), 3.50 (dd, J = 6.3, 1.5 Hz,
2 H, H2-6), 3.44 (d, J = 5.8 Hz, 1 H, H-5), 3.42 (dd, J = 9.8, 2.9 Hz, 1
H, H-3′). 13C NMR (100 MHz, CDCl3): δ/ppm = 138.8–137.7 (Cq Bn),
128.6–127.6 (CH2 Bn), 103.9 (C-1′), 82.5 (C-4′), 80.0 (C-5′), 79.8 (C-2′
), 79.4 (C-3′), 77.6– 74.7 (3 × CH2 Bn), 73.7 (C-3), 73.6 (CH2 Bn), 73.3
(C-5), 73.3–72.9 (3 × CH2 Bn), 70.8 (C-2), 70.8 (C-6′), 68.9 (C-6), 62.3
(C-1). IR: ν̃/cm–1 = 3060, 3029, 2916, 2866, 1497, 1453, 1361, 1208,
1097, 1028. [α]D20 = +14.0 (c = 0.4, CHCl3). HRMS: found 956.4734
[C61H66O9N + Na]+, calculated for [C61H66O9N + H]+ 956.4732. Step
3: 19 (0.20 g, 0.621 mmol, 64 % yield) was synthesized from 2,3,6-
tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl--D-galactopyranosyl)-1-de-
oxynojirimycin (0.932 g, 0.975 mmol) according to the procedure
described for the preparation for compound 9, as a light yellow oil.
1H NMR (400 MHz, MeOD): δ/ppm = 4.44 (d, J = 7.6 Hz, 1 H, H-1′),
3.92 (d, J = 3.7 Hz, 2 H, H2-6), 3.92 (d, J = 3.2, 1.1 Hz, 1 H, H-4′), 3.87
(dd, J = 11.4, 7.4 Hz, 1 H, H-6′a), 3.79 (dd, J = 11.4, 4.7 Hz, 1 H,
H-6′b), 3.67 (ddd, J = 7.4, 4.7, 1.1 Hz, 1 H, H-5′), 3.65 (dd, J = 9.8,
7.6 Hz, 1 H, H-2′), 3.58 (dd, J = 9.7, 3.3 Hz, 1 H, H-3′), 3.55 (ddd, J =
5.1, 9.1, 10.7 Hz, 1 H, H-2), 3.50 (dd, J = 9.5, 8.8 Hz, 1 H, H-4), 3.44
(t, J = 8.7 Hz, 1 H, H-3), 3.17 (dd, J = 12.4, 5.1 Hz, 1 H, H-1a), 2.71
(dt, J = 9.6, 3.8 Hz, 1 H, H-5), 2.54 (dd, J = 12.5, 10.7 Hz, 1 H, H-1b).
13C NMR (100 MHz, MeOD): δ/ppm = 106.1 (C-1′), 83.6 (C-4), 79.6
(C-3), 77.9 (C-5′), 75.7 (C-3′), 73.5 (C-2), 73.3 (C-2′), 71.1 (C-4′), 63.3
(C-6′), 62.8 (C-6), 62.5 (C-5), 51.3 (C-1). [α]D20 = +16.0 (c = 0.2, MeOH).
IR: ν̃/cm–1 = 3306, 2945, 2833, 1653, 1448, 1410, 1113, 1018. HRMS:
found 326.1448 [C12H23NO9 + Na]+, calculated for [C12H23NO9 + H]+
326.1446.
2,3,6-Tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl--D-glucopyran-
osyl)-1-thio-D-glucopyranose (21): Compound 21 (19.5 g,
28.8 mmol, 98 % yield) was synthesized from D-(+)-cellobiose 20
(10.0 g, 29.2 mmol) according to the procedure described for the
preparation for compound 2. RF = 0.36 (1:1, PE/EtOAc). 1H NMR
(400 MHz, CDCl3): δ/ppm = 5.66 (d, J = 8.2 Hz, 1 H, H-1), 5.23 (t, J =
9.2 Hz, 1 H, H-3′), 5.18–4.99 (m, 3 H, H-3, H-4, H-2), 4.97–4.87 (m, 1
H, H-2′), 4.52–4.47 (m, 2 H, H-6′a, H-1′), 4.37 (dd, J = 12.3, 4.4 Hz, 1
H, H-6a), 4.12 (dd, J = 12.2, 4.6 Hz, 1 H, H-6′b), 4.05 (dd, J = 12.5,
2.1 Hz, 1 H, H-6b), 3.82 (dd, J = 15.6, 6.5 Hz, 1 H, H-4′), 3.75 (ddd,
J = 9.8, 4.7, 1.8 Hz, 1 H, H-5), 3.66 (ddd, J = 9.9, 4.4, 2.4 Hz, 1 H,
H-5′). 13C NMR (100 MHz, CDCl3): δ/ppm = 170.6–169.0 (8 × C=O),
100.8 (C-1′), 91.7 (C-1), 76.0 (C-5′), 73.6 (C-4′), 73.0 (C-3′), 72.5 (C-3),
72.1 (C-5), 71.6 (C-2′), 70.5 (C-2), 67.9 (C-4), 61.7 (C-6′), 61.7 (C-6),
21.0–20.6 (8 × CH3).
2,3,6-Tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl-α-D-glucopyran-
osyl)-α/-glucopyranose (22): Step 1: According to the procedure
described for the preparation for compound 3, 2,3,6-tri-O-acetyl-4-
O-(2,3,4,6-tetra-O-acetyl--D-glucopyranosyl)-1-thio-D-glucopyran-
ose (0.67 g, 0.91 mmol, 91 % yield) was synthesized from 21 (0.68 g,
1.00 mmol), as a colorless oil. RF = 0.53 (1:1, PE/EtOAc). 1H NMR
(400 MHz, CDCl3): δ/ppm = 5.20 (dd, J = 10.4, 8.0 Hz, 1 H, H-3′),
5.15 (dd, J = 9.4, 7.2 Hz, 1 H, H-3), 5.06 (t, J = 9.7 Hz, 1 H, H-4), 4.91
(ddd, J = 10.0, 8.6, 3.7 Hz, 2 H, H-2, H-2′), 4.70 (d, J = 10.1 Hz, 1 H,
H-1′), 4.56 (dd, J = 11.9, 2.0 Hz, 1 H, H-6′a), 4.54 (d, J = 7.9 Hz, 1 H,
H-1), 4.38 (dd, J = 12.5, 4.3 Hz, 1 H, H-6a), 4.11 (td, J = 7.1, 1.9 Hz,
1 H, H-6′b), 4.03 (dd, J = 12.4, 2.0 Hz, 1 H, H-6b), 3.75 (m, 1 H, H-4′),
3.69 (ddd, J = 8.9, 3.9, 1.8 Hz, 1 H, H-5), 3.65 (dd, J = 5.7, 2.0 Hz, 1
H, H-5′). 13C NMR (100 MHz, CDCl3): δ/ppm = 170.3–168.8 (7 ×
C=O), 132.8 (CAr SPh), 131.7 (Cq SPh), 128.7, 128.1 (CAr SPh), 100.5
(C-1′), 85.2 (C-1), 76.6 (C-5′), 76.2 (C-4′), 73.4 (C-3′), 72.8 (C-3), 71.7
(C-5), 71.4 (C-2′), 70.0 (C-2), 67.6 (C-4), 61.9 (C-6′), 61.4 (C-6), 20.9–
20.3 (7 × CH3). [α]D20 = +30.6 (c = 1.0, CHCl3). IR: ν̃/cm–1 = 2958,
2872, 1743, 1440, 1368, 1216, 1168, 1038. HRMS: found 751.1878
[C32H40O17S + Na]+, calculated for [C32H40O17S + Na]+ 751.1878.
Step 2: According to the procedure described for the preparation
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for compound 4, 2,3,6-tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl-α-D-
glucopyranosyl)-1-thio-D-glucopyranose (15.4 g, 14.5 mmol, 89 %
yield) was synthesized from the 2,3,6-tri-O-acetyl-4-O-(2,3,4,6-
tetra-O-acetyl--D-glucopyranosyl)-1-thio-D-glucopyranose (11.9 g,
13.3 mmol) as a light yellow oil. RF = 0.63 (4:1, PE/EtOAc). 1H NMR
(400 MHz, CDCl3): δ/ppm = 7.60 (dd, J = 6.5, 3.0 Hz, 2 H, HAr SPh),
7.33–7.16 (m, 32 H, HAr Bn, HAr SPh), 7.13–7.08 (m, 6 H, HAr Bn), 5.64
(d, J = 3.6 Hz, 1 H, H-1′), 4.92–4.76 (m, 6 H, CH2 Bn), 4.70 (d, J =
9.7 Hz, 1 H, H-1), 4.62–4.41 (m, 7 H, CH2 Bn), 4.31 (d, J = 12.1 Hz, 1
H, CH2 Bn), 4.12 (t, J = 9.2 Hz, 1 H, H-4), 3.93 (dd, J = 9.9, 8.9 Hz, 1
H, H-3′), 3.89 (dd, J = 11.3, 4.3 Hz, 1 H, H-6a′), 3.83 (dd, J = 6.5,
4.3 Hz, 1 H, H-6b′), 3.82 (t, J = 8.8 Hz, 1 H, H-3), 3.79 (dd, J = 7.3,
2.7 Hz, 1 H, H-5′), 3.67 (dd, J = 17.1, 8.0 Hz, 1 H, H-4′), 3.60 (dd, J =
11.2, 1.8 Hz, 1 H, H-6a), 3.59 (dd, J = 10.5, 3.3 Hz, 1 H, H-5), 3.58 (t,
J = 10.2 Hz, 1 H, H-2), 3.51 (dd, J = 9.9, 3.7 Hz, 1 H, H-2′), 3.45 (dd,
J = 10.6, 1.8 Hz, 1 H, H-6b). 13C NMR (100 MHz, CDCl3): δ/ppm =
138.7–137.8 (7 × Cq Bn), 133.7 (Cq SPh), 132.0–126.5 (CAr), 97.1
(C-1′), 87.2 (C-1), 86.7 (C-3), 82.0 (C-3′), 80.9 (C-2), 79.4 (C-2′), 78.8
(C-5), 77.7 (C-4′), 75.5–73.3 (7 × CH2 Bn), 72.7 (C-4), 71.1 (C-5′), 69.2
(C-6′), 68.3 (C-6). [α]D20 = +2.87 (c = 2.31, CHCl3). IR: ν̃/cm–1 = 3063,
3030, 2904, 2864, 1452, 1360, 1207, 1140, 1084, 1055, 1026. HRMS:
found 1087.4429 [C61H64O11 + Na]+, calculated for [C61H64O11 +
Na]+ 1087.4425. Step 3: 22 (12.3 g, 12.3 mmol, 93 % yield) was
synthesized from 2,3,6-tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl-α-D-
glucopyranosyl)-1-thio-D-glucopyranose (14.5 g, 13.6 mmol) accord-
ing to the procedure described for the preparation for compound
5, as a light yellow oil. RF = 0.40 and 0.30 (7:3, PE/EtOAc). For the
major anomer: 1H NMR (400 MHz, CDCl3): δ/ppm = 7.31–7.07 (m,
35 H, HAr Bn), 5.66 (dd, J = 8.6, 3.6 Hz, 1 H, H-1′), 5.21 (t, J = 2.9 Hz,
1 H, H-1), 5.02–4.26 (m, 14 H, 7 × CH2 Bn), 4.31 (dd, J = 12.2, 10.0 Hz,
1 H, H-4), 4.13 (t, J = 8.8 Hz, 1 H, H-3), 4.03–3.82 (m, 2 H, H-3′, H-5),
3.80–3.58 (m, 5 H, H-2, H-4′, H-5′, H-6′), 3.55–3.45 (m, 2 H, H-2′, H-
6a), 3.39 (ddd, J = 10.7, 3.6, 1.7 Hz, 1 H, H-6b). 13C NMR (100 MHz,
CDCl3): δ/ppm = 138.9–137.7 (7 × Cq Bn), 128.4–127.1 (CAr Bn), 96.9
(C-1′), 90.7 (C-1), 82.0 (C-3′), 81.4 (C-4), 80.0 (C-2), 79.4 (C-2′), 77.7
(C-4′), 75.6–72.9 (7 × CH2 Bn), 72.9 (C-3), 71.1 (C-5), 69.6 (C-5′), 69.2
(C-6′), 68.1 (C-6). [α]D20 = +32.8 (c = 1.0, CHCl3). IR: ν̃/cm–1 = 3418,
3063, 3030, 2903, 2864, 1497, 1452, 1362, 1265, 1207, 1146, 1088,
1043, 1026. HRMS: found 995.4339 [C61H64O11 + Na]+, calculated for
[C61H64O11 + Na]+ 995.4341.
4-O-(-D-Glucopyranosyl)-1-deoxynojirimycin (24): Step 1: Ac-
cording to the procedure described for the preparation for com-
pound 6, 2,3,6-tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl-α-D-gluco-
pyranosyl)-D-glucitol (8.33 g, 8.55 mmol, 74 % yield) was synthe-
sized from 22 (11.2 g, 11.6 mmol) as a light yellow oil. RF = 0.31
(7:3, PE/EtOAc). 1H NMR (400 MHz, CDCl3): δ/ppm = 7.36–7.07 (m,
35 H, HAr Bn), 4.82 (d, J = 3.1 Hz, 1 H, H-1′), 4.96–4.35 (m, 14 H, 7 ×
CH2 Bn), 4.12 (dd, J = 8.6, 4.0 Hz, 1 H, H-3′), 3.98 (ddd, J = 10.2, 3.2,
2.1 Hz, 1 H, H-5), 3.96–3.90 (m, 4 H, H-5′, H-4, H-3′, H-4′), 3.71 (dt,
J = 29.8, 6.9 Hz, 2 H, H-1), 3.52–3.62 (m, 6 H, H2-6, H2-6′, H-2, H-2′).
13C NMR (100 MHz, CDCl3): δ/ppm = 138.2–137.6 (7 × Cq Bn), 129.1–
125.4 (CAr Bn), 99.2 (C-1′), 82.0 (C-3), 79.9 (C-3′), 79.7 (C-4′), 79.4
(C-2), 78.8 (C-4), 77.8 (C-2′), 75.7–72.8 (7 × CH2 Ph), 71.8 (C-3′), 71.6
(C-6), 71.2 (C-5), 68.3 (C-6′), 61.6 (C-1). IR: ν̃/cm–1 = 3420, 3063, 3030,
2862, 1454, 1207, 1086, 1070, 1028. [α]D20 = +38.1 (c = 1.03, CHCl3).
HRMS: found 997.4497 [C61H66O11 + Na]+, calculated for [C61H66O11
+ Na]+ 997.4497. Step 2: According to the procedure described
for the preparation for compound 8, 2,3,6-tri-O-benzyl-4-O-(2,3,4,6-
tetra-O-benzyl--D-glucopyranosyl)-1-deoxynojirimycin (0.43 g,
0.45 mmol, 44 % yield) was synthesized from 2,3,6-tri-O-benzyl-4-
O-(2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyl)-D-glucitol (1.0 g,
1.02 mmol) as a light yellow oil. RF = 0.38 (1:1 PE, EtOAc). 1H NMR
(400 MHz, CDCl3): δ/ppm = 7.49–7.26 (m, 35 H, HAr Bn), 5.94 (d, J =
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3.6 Hz, 1 H, H-1′), 5.30–4.46 (m, 14 H, 7 × CH2 Bn), 4.11 (dd, J = 9.8,
8.5 Hz, 1 H, H-3′), 3.98 (dd, J = 9.6, 8.7 Hz, 1 H, H-4), 3.93–3.87 (m,
3 H, H-5′, H-6a, H-3), 3.84 (dd, J = 8.7, 1.3 Hz, 1 H, H-4′), 3.81 (dd,
J = 8.7, 5.6 Hz, 1 H, H-6b), 3.73 (dd, J = 10.6, 2.8 Hz, 1 H, H-6a′), 3.72
(td, J = 5.3, 2.2 Hz, 1 H, H-2), 3.67 (dd, J = 9.8, 3.6 Hz, 1 H, H-2′),
3.61 (dd, J = 10.4, 1.3 Hz, 1 H, H-6b′), 3.42 (dd, J = 12.3, 5.1 Hz, 1 H,
H-1a), 3.03 (ddd, J = 9.0, 5.7, 2.8, 1 H, H-5), 2.70 (dd, J = 12.3, 10.6 Hz,
1 H, H-1b). 13C NMR (100 MHz, CDCl3): δ/ppm = 139.1–137.9 (7 ×
Cq Bn), 128.3–126.5 (CAr Bn), 96.6 (C-1′), 87.0 (C-3), 82.0 (C-3′), 80.9
(C-2), 79.3 (C-2′), 77.7 (C-4′), 75.5, 74.9 (2 × CH2 Bn), 74.2 (C-4), 73.8–
72.5 (5 × CH2 Ph), 71.0 (C-5′), 70.5 (C-6), 68.1 (C-6′), 59.0 (C-5), 47.8
(C-1). [α]D20 = +26.0 (c = 0.7, CHCl3). IR: ν̃/cm–1 = 2918, 2866, 1454,
1362, 1240, 1090, 1072, 1047, 1026. HRMS: found 956.4736
[C61H66NO9 + Na]+, calculated for [C61H66NO9 + Na]+ 956.4732. Step
3: Compound 24 (0.22 g, 0.67 mmol, 65 % yield) was synthesized
from 2,3,6-tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl--D-glucopyran-
osyl)-1-deoxynojirimycin (1.00 g, 1.04 mmol) according to the pro-
cedure described for the preparation for compound 8, as a light
yellow oil. 1H NMR (600 MHz, D2O): δ/ppm = 4.46 (d, J = 7.9 Hz, 1
H, H-1′), 3.88 (dd, J = 12.3, 3.1 Hz, 1 H, H-6a), 3.84 (dd, J = 12.4,
2.2 Hz, 1 H, H-6′a), 3.66 (dd, J = 12.4, 5.7 Hz, 1 H, H-6′b), 3.66–3.62
(m, 1 H, H-2), 3.62 (dd, J = 10.4, 8.9 Hz, H-5′), 3.49 (t, J = 9.1 Hz, 1
H, H-3), 3.42 (q, J = 9.5 Hz, 1 H, H-3′), 3.42–3.39 (m, 1 H, H-5′), 3.35
(dd, J = 9.8, 9.1 Hz, H-4′), 3.26 (dd, J = 12.7, 5.0 Hz, H-1a), 3.26 (dd,
J = 9.4, 7.9 Hz, H-2′), 3.02 (ddd, J = 10.3, 5.0, 2.9 Hz, 1 H, H-5), 2.70
(dd, J = 12.5, 11.2 Hz, 1 H, H-1b). 13C NMR (150 MHz, D2O): δ/ppm =
102.6 (C-1), 78.5 (C-4), 76.0 (C-5′), 75.6 (C-3′), 75.5 (C-3), 73.2 (C-2′),
69.4 (C-4′), 68.4 (C-2), 60.5 (C-6′), 59.2 (C-5), 58.4 (C-6), 46.6 (C-1).
[α]D20 = +25.3 (c = 1.0, MeOH). IR: ν̃/cm–1 = 3302, 2966, 1636, 1558,
1203, 1161, 1022. HRMS: found 326.1446 [C12H23NO9 + H]+, calcu-
lated for [C12H23NO9 + H]+ 326.1446.
Phenyl-3-O-benzyl-4,6-O-benzylidene-1-thio--D-glucopyranos-
ide (26): The glucose acceptor was prepared following the literature
procedures. [ 1 1 ] Step 1: -D-Glucose penta-acetate (1.00 g,
2.56 mmol) and PhSH (0.4 mL, 4 mmol) were dissolved in DCM
(20 mL). The mixture was cooled to 0 °C and BF3·Et2O (0.46 mL,
3.7 mmol) was added dropwise. After 5 hours, TLC analysis showed
complete consumption of the starting compound. The mixture was
washed with sat. aq. NaHCO3, organic layer was dried (Na2SO4),
filtered and concentrated. The crude product was purified with sil-
ica gel column chromatography to gain the phenyl-1-thio-2,3,4,6-
tetra-(O-acetyl)--D-glucopyranoside as white crystals (1.02 g,
2.33 mmol, yield 91 %). RF = 0.7 (5:3, PE/EtOAc). 1H NMR (400 MHz,
CDCl3): δ/ppm = 7.55–7.49 (m, 2 H, HAr SPh), 7.34 (dd, J = 5.1, 2.0 Hz,
3 H, HAr SPh), 5.24 (t, J = 9.3 Hz, 1 H, H-3), 5.06 (t, J = 9.8 Hz, 1 H,
H-4), 4.99 (dd, J = 10.1, 9.2 Hz, 1 H, H-2), 4.73 (d, J = 10.1 Hz, 1 H,
H-1), 4.24 (dd, J = 12.3, 5.0 Hz, 1 H, H-6a), 4.20 (dd, J = 12.3, 2.7 Hz,
1 H, H-6b), 3.75 (ddd, J = 10.1, 5.0, 2.7 Hz, 1 H, H-5), 2.11 (s, 3 H,
CH3), 2.10 (s, 3 H, CH3), 2.04 (s, 3 H, CH3), 2.01 (s, 3 H, CH3). 13C NMR
(100 MHz, CDCl3): δ/ppm = 170.6, 170.2, 169.4, 169.3 (4 × C=O),
131.6 (Cq SPh), 128.9–128.4 (CAr SPh), 85.7 (C-1), 75.8 (C-5), 74.0 (C-
3), 69.9 (C-2), 68.2 (C-4), 62.1 (C-6), 20.7–20.6 (4 × CH3). Step 2:
NaOMe (0.28 g, 5.12 mmol) was added to a solution of the phenyl-
1-thio-2,3,4,6-tetra-(O-acetyl)--D-glucopyranoside (2.56 mmol) in
MeOH (20 mL). After 24 hours, TLC analysis showed complete con-
sumption. The solution was neutralized with amberlite H+ resin,
filtered and concentrated. The crude deprotection product was
used for the next reaction step without further purification. RF =
0.6 (5:1, EtOAc/MeOH). 1H NMR (400 MHz, MeOD): δ/ppm = 7.60–
7.57 (m, 2 H, HAr SPh), 7.35–7.26 (m, 3 H, HAr SPh), 4.63 (d, J =
9.6 Hz, 1 H, H-1), 3.91 (dd, J = 12.4, 1.6 Hz, 1 H, H-6a), 3.71 (dd, J =
12.0, 5.6, 1 H, H-6b), 3.43 (t, J = 8.8, 1 H, H-4), 3.37–3.29 (m, 2 H, H-
3, H-5), 3.26 (dd, J = 9.6, 8.8, 1 H, H-2). 13C NMR (100 MHz, MeOD):
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δ/ppm = 133.8 (Cq Ph), 131.3, 128.5, 127.0 (CAr SPh), 88.0 (C-1), 80.7
(C-3), 78.3 (C-4), 72.4 (C-2), 70.0 (C-5), 61.5 (C-6). Step 3: PhCH(OMe)2
(5.70 mL, 38 mmol) was added to the solution of phenyl-1-thio--
D-glucopyranoside (8.65 g, 31.6 mmol) in DMF (20 mL). pTsOH was
added to adjust the pH to 4. The mixture was heated to 60 °C and
the pressure reduced to 20 mbar. After 4.5 hours, TLC analysis
showed complete consumption. The mixture was neutralized with
TEA, diluted with EtOAc, washed successively with distilled water
and brine, dried (Na2SO4), filtered, concentrated to get light yellow
oil as crude product. The crude product was recrystallized with
warm ethanol to get pure 4,6-O-benzylidene thioglucopyranoside
as white solid (19 mmol, yield 59 % over two steps). RF = 0.67 (2:1,
EtOAc/PE). 1H NMR (400 MHz, CDCl3): δ/ppm = 7.58–7.55 (m, 2 H,
HAr Ph), 7.59–7.57 (m, 3 H, HAr Ph), 7.41–7.37 (m, 5 H, HAr Ph), 5.57
(s, 1 H, H-7), 4.69 (d, J = 9.6 Hz, 1 H, H-1), 4.44 (dd, J = 10.4, 4.4 Hz,
1 H, H-6a) 3.91 (t, J = 8.8 Hz, 1 H, H-3) 3.85 (dd, J = 7.2 Hz, 3.2 Hz,
1 H, H-6b), 3.51–3.55 (m, 2 H, H-4, H-5), 3.53 (dd, J = 11.8, 8.4 Hz, 1
H, H-2). 13C NMR (100 MHz, CDCl3): δ/ppm = 136.8, 134.2 (Cq Ph),
133.1–126.3 (CAr Ph), 102.0 (C-7), 88.7 (C-1), 80.2 (C-4), 74.6 (C-3),
72.6 (C-2), 70.6 (C-5), 68.6 (C-6). Step 4: Bu2SnO (0.35 g, 1.40 mmol)
was added to a solution of 4,6-O-benzylidene thioglucopyranoside
(0.48 g, 1.33 mmol) in toluene (17 mL), the reaction mixture was
stirred overnight at 115 °C. Then toluene was evaporated, the resi-
due was dissolved in DMF (10 mL), and CsF (0.31 g, 2.04 mmol),
BnBr (0.3 mL, 2.5 mmol) was added. The reaction mixture was
stirred at 115 °C for 12 hours. After TLC analysis showed complete
consumption, the reaction mixture was diluted with EtOAc, washed
successively with NaHCO3 solution and brine. The organic layer was
dried (Na2SO4), concentrated and the residue was purified with a
short column (8:1, PE/EtOAc) to gain 26 (0.44 g, yield 73.3 %) as
light yellow crystal. RF = 0.66 (4:1, PE/EtOAc). 1H NMR (400 MHz,
CDCl3): δ/ppm = 5.60 (s, 1 H, Ct H Ph), 4.99 (d, J = 11.5 Hz, 1 H, CHH
Bn), 4.83 (d, J = 11.6 Hz, 1 H, CHH Bn), 4.67 (d, J = 9.7 Hz, 1 H, H-
1), 4.42 (dd, J = 10.5, 5.0 Hz, 1 H, H-6), 3.83 (t, J = 10.3 Hz, 1 H, H-
6), 3.76–3.63 (m, 2 H, H-3, H-4), 3.58–3.53 (m, 2 H, H-2, H-5). 13C
NMR (100 MHz, CDCl3): δ/ppm = 138.2, 137.2 (Cq Ph), 133.2–126.0
(CAr Ph), 101.3 (C-7), 88.5 (C-1), 81.7 (C-3), 81.1 (C-4), 74.8 (CH2 Bn),
72.3 (C-2), 70.7 (C-5), 68.6 (C-6).
2,3-Di-O-benzoyl-4,6-O-di-tert-butylsilanediyl-D-galactopyrano-
side-N-phenyl-2,2,2-trifluoroacetimidate (25): The galactose
imidate is prepared following the literature procedures.[10] Step 1:
Phenyl-1-thio-2,3,4,6-tetra-O-acetyl--D-galactopyranoside (1.2 g,
2.5 mmol, 100 %) was synthesized from -D-galactose pentaacetate
(1.00 g, 2.56 mmol), thiophenol (0.4 mL, 3.91 mmol) and BF3·Et2O
(0.46 mL, 3.72 mmol) according to the procedure described for the
preparation of the phenyl-1-thio-2,3,4,6-tetra-(O-acetyl)--D-gluco-
pyranoside, as white crystal. RF = 0.68 (5:3, PE/EtOAc). 1H NMR
(400 MHz, CDCl3): δ/ppm = 7.52–7.52 (m, 2 H, HAr), 7.34–7.32 (m, 3
H, HAr), 5.44 (d, J = 3.2, 1 H, H-1), 5.28 (t, J = 10 Hz, 1 H, H-2), 5.08
(dd, J = 10, 3.6 Hz, 1 H, H-3), 4.75 (d, J = 10.0 Hz, 1 H, H-4), 4.23
(dd, J = 11.2, 7.2 Hz, 1 H, H-6a), 4.15 (dd, J = 11.6, 6 Hz, 1 H, H-6b),
3.98 (t, J = 6.4 Hz, 1 H, H-5), 2.14 (s, 3 H, CH3), 2.11 (s, 3 H, CH3),
2.06 (s, 3 H, CH3), 1.99 (s, 3 H, CH3). 13C NMR (100 MHz, CDCl3): δ/
ppm = 170.4–169.5 (4 × C=O), 132.6 (CAr), 132.5 (Cq Ph), 129.0, 128.2
(CAr), 86.6 (C-1), 74.4 (C-5), 72.0 (C-3), 67.3 (C-2), 67.2 (C-4),
61.7 (C-6), 20.9 (CH3), 20.7 (CH3), 20.7 (CH3), 20.7 (CH3). Step 2:
Phenyl-1-thio--D-galactopyranoside was synthesized from the
phenyl-1-thio-2,3,4,6-tetra-O-acetyl--D-galactopyranoside (59.00 g,
133.95 mmol), using thiophenol (0.4 mL, 3.91 mmol) and BF3·Et2O
(0.46 mL, 3.72 mmol) according to the procedure described for the
deprotection of the phenyl-1-thio--D-glucopyranoside. The crude
product was used in next step without further purification. The
crude thiogalactopyranoside (3.12 g, 11.5 mmol) was co-evaporated
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with DMF. The mixture was dissolved in pyridine (20 mL). The solu-
tion was cooled to –20 °C and tBuSi(OTf)2 (3.5 mL, 9.9 mmol) was
added. After 2 hours, TLC analysis showed complete consumption
of the starting compound. MeOH was added to quench the reac-
tion. The solution was concentrated and diluted with EtOAc,
washed with HCl (1 M) and sat. aq. NaHCO3. The organic layer was
dried (Na2SO4), filtered and concentrated. The residue was purified
with silica gel column chromatography (1:4 → 1:3, EtOAc/PE) to
gain the 4,6-O-di-tert-butylsilylene thiogalactopyranoside (2.49 g,
6.04 mmol, yield 53 %) as light yellow oil. RF = 0.34 (1:1, PE/EtOAc).
1H NMR (400 MHz, CDCl3): δ/ppm = 7.62–7.52 (m, 2 H, HAr), 7.39–
7.30 (m, 3 H, HAr), 4.58 (d, J = 9.8 Hz, 1 H, H-1), 4.46 (dd, J = 3.5,
1.1 Hz, 1 H, H-4), 4.29 (dd, J = 2.0, 1.1 Hz, 2 H, H-6), 3.77 (dd, J =
9.8, 8.9 Hz, 1 H, H-2), 3.56 (dd, J = 8.9, 3.5 Hz, 1 H, H-3), 3.50 (td, J =
2.0, 1.1 Hz, 1 H, H-5), 1.08 (s, 9 H, 3 × CH3), 1.06 (s, 9 H, 3 × CH3).
13C NMR (100 MHz, CDCl3): δ/ppm = 133.1 (Cq), 132.6–127.9 (CHAr),
89.1 (C-1), 75.2 (C-5), 75.1 (C-3), 72.5 (C-4), 70.7 (C-2), 67.1 (C-6),
27.6–20.7 (6 × CH3, tert-Bu). Step 3: 4,6-O-di-tert-butylsilylene thio-
galactopyranoside (15.74 g, 38.15 mmol) was dissolved in DMF
(20 mL). BnBr (9 mL, 76 mmol) and TBAI (16.75 g, 68.68 mmol) were
added. The mixture was cooled to 0 °C and NaH (8.2 g, 0.21 mmol)
was added in small potions. After an overnight reaction, TLC analy-
sis showed complete consumption. The mixture was quenched with
water, diluted with EtOAc and washed with brine. The organic layer
was dried (Na2SO4), filtered and concentrated. The residue was puri-
fied with silica gel column chromatography (20:1 → 10:1, PE/EtOAc)
to gain 2,3-di-O-benzyl-4,6-O-di-tert-butylsilylene thiogalacto-
pyranoside (12.66 g, 21.35 mmol, yield 56 %) as thick oil. RF = 0.4
(5:1, PE/EtOAc). 1H NMR (400 MHz, CDCl3): δ/ppm = 7.61–7.27 (m,
12 H, HAr), 4.94 (s, 2 H, CH2 Bn), 4.80 (q, J = 18.8 Hz, 12 Hz, 2 H, CH2
Bn), 4.71 (d, J = 9.6 Hz, 1 H, H-1), 4.53 (d, J = 2.8 Hz, 1 H, H-4), 4.24
(m, 2 H, H-6), 3.89 (t, J = 9.6 Hz, 1 H, H-2), 3.52 (dd, J = 9.2, 3.2 Hz,
1 H, H-3), 3.32 (s, 1 H, H-5), 1.17(s, 9 H, tert-Bu), 1.12 (s, 9 H, tert-Bu).
13C NMR (100 MHz, CDCl3): δ/ppm = 138.4, 134.9 (Cq), 132.1–127.3
(CAr), 88.7 (C-1), 82.8 (C-3), 77.0 (C-2), 76.0 (CH2 Bn), 74.8 (C-5), 71.1
(CH2 Bn), 70.0 (C-4), 67.4 (C-6), 27.7, 27.7 (CH3, tert-Bu), 23.5 (Cq, tert-
Bu), 20.8 (Cq, tert-Bu). Step 4: 2,3-Di-O-benzyl-4,6-O-di-tert-butyl-
silylene thiogalactopyranoside (0.61 g, 1.0 mmol, co-evaporated 3 ×
with toluene) was dissolved in DCM (50 mL). The solution was
cooled to 0 °C. N-Iodosuccinimide (0.23 g, 1.03 mmol) and TFA
(77 μL, 1.0 mmol) were added to the solution. After 1 hour, TLC
analysis showed complete consumption. The reaction was
quenched with TEA and sat. aq. Na2S2O3 solution was added to the
mixture. The mixture was extracted with EtOAc, and the organic
layer was dried (Na2SO4), filtered and concentrated. The resulting
residue was purified with silica gel column chromatography (10:1
→ 2:1, PE/EtOAc) to gain the 2,3-di-O-benzyl-4,6-O-di-tert-butyl-
silylene-D-galactopyranoside (0.451 g, 0.903 mmol, yield 88 %). RF =
0.28 (toluene). 1H NMR (400 MHz, CDCl3): δ/ppm = 7.37–7.29 (m, 10
H, HAr Bn), 5.23 (d, J = 3.6 Hz, 1 H, H-1), 4.92 (d, J = 11.6 Hz, 2 H,
CH2 Bn), 4.81–4.72 (m, 2 H, CH2 Bn), 4.54 (d, J = 3.0 Hz, 1 H, H-4),
4.21–4.12 (m, 2 H, H-6), 4.02 (dd, J = 9.6, 3.6 Hz, 1 H, H-2), 3.87 (d,
J = 3.2 Hz, 1 H, H-5), 3.84 (d, J = 2.8 Hz, 1 H, H-3), 1.12, 1.08 (s, 9 H,
CH3). 13C NMR (100 MHz, CDCl3): δ/ppm = 138.9, 138.3 (Cq Bn),
128.4–127.6 (CAr Bn), 92.1 (C-1), 77.5 (C-3), 74.8 (C-2), 74.8 (CH2 Bn),
71.0 (C-4), 71.0 (CH2 Bn), 67.4 (C-6), 67.3 (C-5), 27.7 (CH3), 27.7 (CH3),
27.6, 27.4 (CH3, tert-Bu), 23.5, 20.7 (Cq, tert-Bu). Step 5: Cs2CO3
(0.28 g, 0.85 mmol) and trifluoro-phenylacetimidoyl chloride (0.20 g,
0.96 mmol) was added to a solution of the 2,3-di-O-benzyl-4,6-O-
di-tert-butylsilylene-D-galactopyranoside (0.27 g, 0.54 mmol) in
acetone (3 mL). The reaction mixture was kept at 0 °C under argon
atmosphere. After 3 hours, the reaction mixture was filtered
through a pad of celite to get rid of the Cs salt. The filtrate was
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concentrated and purified on a short column (20:1 → 2:1, PE/EtOAc)
to obtain 25 (0.22 g, 0.26 mmol, yield 65 %) as anomeric mixture
at ratio 1:1. RF = 0.56, 0.38 (10:1, PE/EtOAc). For the upper spot on
TLC, 1H NMR (400 MHz, CDCl3): δ/ppm = 7.52–6.78 (m, 15 H, HAr
Bn), 6.55 (br-s, 1 H, H-1), 4.89 (d, J = 11.8 Hz, 1 H, CHH Bn), 4.85–
4.72 (m, 3 H, 3 × CHH Bn), 4.62 (br-s, 1 H, H-4), 4.33–4.18 (m, 3 H,
H-6, H-2), 3.91 (d, J = 10.1 Hz, 1 H, H-3), 3.81 (br-s, 1 H, H-5), 1.10
(s, 9 H, 3 × CH3), 1.02 (s, 9 H, 3 × CH3). 13C NMR (100 MHz, CDCl3):
δ/ppm = 171.1 (C=N), 143.8, 138.6, 138.2 (Cq Bn), 129.1–120.6 (CHAr
Bn), 100.0 (CF3), 94.8 (H-1), 77.3 (C-3), 73.7 (CH2 Bn), 73.6 (C-2), 71.1
(CH2 Bn), 70.7 (C-4), 70.0 (C-5), 66.8 (C-6), 27.6, 27.2 (CH3, tert-Bu),
23.5, 20.7 (Cq, tBu).
3-Benzyl-4,6-O-benzylidene-2-O-(2,3-di-benzyl-4,6-O-di-tert-
butylsilyl-galactopyranpsyl)-1-thio-D-glucopyranose (27): Com-
pounds 26 (0.40 g, 0.90 mmol) and 25 (1.20 g, 1.79 mmol, co-
evaporated 3 × with toluene). The mixture was dissolved in dried
DCM (4 mL) and cooled to 0 °C, followed by adding of trimethylsilyl
trifluoromethanesulfonate (0.045 mL, 0.25 mmol) dropwise. After an
overnight reaction, TLC analysis showed complete consumption of
25. The reaction was quenched with TEA and concentrated. The
resulting residue was purified with silica gel column chromatogra-
phy (40:1 → 10:1, PE/EtOAc). Yield 69 % (0.56 g, 0. 61 mmol). RF =
0.15 (10:1, PE/EtOAc). 1H NMR (400 MHz, CDCl3): δ/ppm = 7.70–7.04
(m, 25 H, HAr), 5.89 (d, J = 4 Hz, 1 H, H-1′), 5.65 (s, 1 H, H-7), 5.09
(d, J = 10 Hz, 1 H, CHH Bn), 4.97 (d, J = 9.2 Hz, 1 H, H-1), 4.89 (s, 2
H, CH2 Bn), 4.81 (q, J = 12, 13.5 Hz, 2 H, CH2 Bn), 4.43 (dd, J = 10.8,
5.2 Hz, 1 H, H-6a), 4.33 (d, J = 10.4 Hz, 1 H, CHH Bn), 4.07 (dd, J =
10.0, 3.6 Hz, 1 H, H-2′), 4.02 (d, 8.0 Hz, 1 H, H-4′), 3.89–3.72 (m, 6 H,
H-3, H-2, H-5′, H-6b, H-3′, H-4), 3.56 (dd, J = 12.8, 1.6 Hz, 1 H, H-6′
a), 3.60–3.53 (m, 1 H, H-5), 3.02 (dd, J = 12.6, 2.2 Hz, 1 H, H-6′b),
1.02 (s, 9 H, 3 × CH3), 0.99 (s, 9 H, 3 × CH3). 13C NMR (100 MHz,
CDCl3): δ/ppm = 139.5–126.0 (CAr), 101.1 (C-7), 96.2 (C-1′), 87.6 (C-
1′), 82.2 (C-3), 81.0 (C-4), 77.0 (C-3′), 76.2 (CH2 Bn), 74.2 (C-2′), 73.7
(CH2 Bn), 72.7 (C-2), 71.2 (CH2 Bn), 71.0 (C-4′), 70.0 (C-5), 68.7 (C-6),
66.9 (C-3′), 66.5 (C-6′), 27.7, 27.3 (CH3, tert-Bu), 23.3 (Cq, tert-Bu), 20.6
(Cq, tert-Bu). [α]D20 = +34.0 (c = 2.60, CHCl3). IR: ν̃/cm–1 = 2933, 2858,
1735, 1473, 1453, 1440, 1373, 1241, 1170, 1149, 1097, 1044, 1025.
HRMS: found 933.4068 [C5 4H6 4O1 0SSi + H]+, calculated for
[C54H64O10SSi + H]+ 933.4068.
Phenyl-1-thio-2-O-(2,3,4,6-tetra-O-benzyl-α-galactopyranosyl)-
3,4,6-tri-benzyl-D-glucopyranose (28): Step 1: TBAF (1 M in THF,
1.2 mL, 1.2 mmol) was added dropwise to a solution of 27 (0.16 g,
0.17 mmol) in THF (2 mL) at 0 °C, and the yellow solution was kept
stirred at room temperature overnight. The reaction mixture was
then diluted with EtOAc, washed with brine, dried (Na2SO4) filtered
concentrated and the residue was purified with a silica gel column
chromatography (5:2 → 1:1, PE/EtOAc) to get the 3-benzyl-4,6-O-
benzylidene-2-O-(2,3-di-benzyl-galactopyranpsyl)-1-thio-D-gluco-
pyranose (0.11 g, 0.14 mmol, yield 82 %). RF = 0.17 (5:2, PE/EtOAc).
1H NMR (400 MHz, CDCl3): δ/ppm = 7.52–7.17 (m, 25 H, HAr), 6.01
(d, J = 3.8 Hz, 1 H, H-1′), 5.63 (s, 1 H, H-7), 5.10 (d, J = 10.7 Hz, 1 H,
CHH Bn), 4.96 (d, J = 9.3 Hz, 1 H, H-1), 4.87 (d, J = 11.7 Hz, 1 H, CHH
Bn), 4.84 (d, J = 11.6 Hz, 1 H, CHH Bn), 4.77 (d, J = 11.7 Hz, 1 H,
CHH Bn), 4.71 (d, J = 11.6 Hz, 1 H, CHH Bn), 4.48 (d, J = 10.7 Hz, 1
H, CHH Bn), 4.41 (dd, J = 10.5, 5.0 Hz, 1 H, H-6a), 4.06 (t, J = 4.8 Hz,
1 H, H-5′), 3.96–3.90 (m, 3 H, H-2, H-2′, H-3), 3.84 (d, J = 10.2 Hz, 1
H, H-6b), 3.81–3.78 (m, 1 H, H-4), 3.75 (dd, J = 10.0, 3.2 Hz, 1 H, H-
3′), 3.59 (dd, J = 3.2, 1.5 Hz, 1 H, H-4′), 3.55 (dt, J = 9.8, 4.8 Hz, 1 H,
H-5), 3.30 (dd, J = 11.8, 5.4 Hz, 1 H, H-6′a), 3.23 (dd, J = 11.8, 4.3 Hz,
1 H, H-6′b). 13C NMR (100 MHz, CDCl3): δ/ppm = 137.9–125.9 (CAr),
101.1 (C-7), 95.7 (C-1′), 87.5 (C-1), 82.0 (C-4), 81.9 (C-3) 76.7 (C-3′),
76.0 (CH2 Bn), 75.4 (C-2′), 73.3 (CH2 Bn), 73.2 (C-2), 72.8 (CH2 Bn),
70.0 (C-5), 69.9 (C-4′), 68.6 (C-6), 68.4 (C-5′), 63.1 (C-6′). [α]D20 = +22.1
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(c = 0.85, CHCl3). IR: ν̃/cm–1 = 3061, 2894, 1497, 1453, 1371, 1266,
1219, 1148, 1099, 1017. HRMS: found 815.2860 [C46H48O10S + Na]+,
calculated for [C46H48O10S + Na]+ 815.2860. Step 2: p-Toluenesulf-
onic acid monohydrate (0.065 g, 0.34 mmol) was added to a solu-
tion of the 3-benzyl-4,6-O-benzylidene-2-O-(2,3-di-benzyl-galacto-
pyranpsyl)-1-thio-D-glucopyranose (0.10 g, 0.13 mmol) in methanol
and DCM (10 mL, 1:1, v/v), and the reaction mixture was kept stirred
at room temperature overnight. After quenched with TEA, the reac-
tion mixture was concentrated and purify with silica gel column
chromatography (1:1, pentane/EtOAc) to gain phenyl-1-thio-2-O-
(2,3-di-O-benzyl-α-galactopyranosyl)-3-benzyl-D-glucopyranose
(0.08 g, yield 90 %). RF = 0.1 (1:1, PE/EtOAc). 1H NMR (400 MHz,
CDCl3): δ/ppm = 7.53–7.16 (m, 15 H, HAr), 5.97 (d, J = 3.7 Hz, 1 H,
H-1′), 5.06 (d, J = 11.2 Hz, 1 H, CHH Bn), 4.91 (d, J = 9.7 Hz, 1 H, H-
1), 4.87 (d, J = 11.7 Hz, 1 H, CHH Bn), 4.82 (d, J = 11.8 Hz, 1 H, CHH
Bn), 4.76 (d, J = 11.8 Hz, 1 H, CHH Bn), 4.71 (d, J = 11.7 Hz, 1 H,
CHH Bn), 4.58 (d, J = 11.2 Hz, 1 H, CHH Bn), 4.05 (td, J = 5.2, 4.7,
2.3 Hz, 1 H, H-5′), 3.93 (dd, J = 10.1, 3.9 Hz, 1 H, H-2′), 3.90–3.79 (m,
4 H, H-6a, H-2, H-6b, H-3), 3.76 (dd, J = 10.0, 3.2 Hz, 1 H, H-3′), 3.66
(t, J = 9.0 Hz, 1 H, H-4), 3.54 (d, J = 2.9 Hz, 1 H, H-4′), 3.42–3.34 (m,
2 H, H-6′a, H-5), 3.26 (dd, J = 11.8, 4.0 Hz, 1 H, H-6′b). 13C NMR
(100 MHz, CDCl3): δ/ppm = 138.1–126.3 (CAr), 95.5 (C-1′), 87.4 (C-1),
85.4 (C-4), 79.3 (C-5), 76.6 (C-3′), 76.2 (CH2 Bn), 75.4 (C-2′), 73.2 (CH2
Bn), 73.1 (C-2), 72.7 (CH2 Bn), 71.1 (C-3), 69.1 (C-4′), 68.6 (C-5′), 62.9
(C-6′), 62.0 (C-6). [α]D20 = +16.3 (c = 2.45, CHCl3). IR: ν̃/cm–1 = 3432,
3031, 2923, 1584, 1497, 1454, 1275, 1094, 1028. HRMS: found
727.2542 [C39H44O10 + Na]+, calculated for [C39H44O10 + Na]+
727.2547. Step 3: NaH (60 % on mineral oil, 48.8 mg, 1.22 mmol)
was added to a solution of phenyl-1-thio-2-O-(2,3-di-O-benzyl-α-
galactopyranosyl)-3-benzyl-D-glucopyranose (0.08 g, 0.11 mmol) in
1 mL of DMF at 0 °C under argon atmosphere, the suspension was
kept stirring at 0 °C for 1 hour. Then BnBr (0.067 mL, 0.56 mmol) was
added. The reaction mixture was kept stirred at room temperature
overnight. After quenching with water, the reaction mixture was
extracted with EtOAc, washed with water and brine, dried (Na2SO4),
filtered, concentrated and purified with silica gel column chroma-
tography (20:1, pentane/EtOAc) to get pure 28 (0.11 g, 0.10 mmol,
yield 92 %). RF = 0.62 (5:1, PE/EtOAc). 1H NMR (400 MHz, CDCl3): δ/
ppm = 7.59–7.09 (m, 40 H, HAr), 6.01 (d, J = 3.7 Hz, 1 H, H-1′), 4.98
(d, J = 11.6 Hz, 1 H, CHH Bn), 4.92–4.53 (m, 10 H, 5 × CH2 Bn), 4.49
(d, J = 11.4 Hz, 1 H, CHH Bn), 4.33 (t, J = 6.5 Hz, 1 H, H-5′), 4.30 (d,
J = 12.0 Hz, 1 H, CHH Bn), 4.22 (d, J = 11.8 Hz, 1 H, CHH Bn), 4.12
(dd, J = 10.2, 3.6 Hz, 1 H, H-2′), 3.97 (t, J = 9.1 Hz, 1 H, H-2), 3.89
(dd, J = 10.2, 2.7 Hz, 1 H, H-3′), 3.81–3.72 (m, 3 H, H-6a, H-6b, H-4),
3.65 (t, J = 9.3 Hz, 1 H, H-3), 3.60 (dd, J = 2.9, 1.3 Hz, 1 H, H-4′), 3.55
(ddd, J = 9.8, 4.5, 2.1 Hz, 1 H, H-5), 3.44 (dd, J = 9.5, 6.4 Hz, 1 H, H-
6′a), 3.28–3.23 (m, 1 H, H-6′b). 13C NMR (100 MHz, CDCl3): δ/ppm =
138.9–127.1 (CAr), 95.6 (C-1′), 87.1 (C-1), 85.2 (C-4), 79.0 (C-5), 78.5
(C-3), 78.3 (C-3′), 76.3 (C-2′), 75.5 (CH2 Bn), 75.2 (C-4′), 74.9 (CH2 Bn),
74.7 (CH2 Bn), 73.5 (CH2 Bn), 73.4 (C-2), 73.1 (CH2 Bn), 73.0 (CH2 Bn),
69.3 (C-5′), 69.1 (C-6′), 68.9 (C-6). [α]D20 = +20.6 (c = 0.80, CHCl3).
HRMS: found 1087.4430 [C67H6 8O10S + Na]+, calculated for
[C67H68O10S + Na]+ 1087.4431.
2-O-(α-D-Galactopyranosyl)-1-deoxynojirimycin (29): Step 1: NIS
(0.13 g, 0.53 mmol) and TFA (35 μL) was added to a solution of 28
(0.44 g, 0.41 mmol) in dried DCM (5 mL) at 0 °C under argon atmos-
phere. The reaction was then kept stirred at room temperature for
2 hours. Piperidine was added to quench the reaction at 0 °C, after
which sat. aq. Na2S2O3 solution was added. The reaction mixture
was then diluted with EtOAc, washed with HCl solution (1 M) and
brine. The organic layer was dried (Na2SO4), filtered and concen-
trated. The crude product was purified with silica gel column chro-
matography (4:1 → 2:1, PE/EtOAc) to gain 2-O-(2,3,4,6-Tetra-O-
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benzyl-α-galactopyranosyl)-3,4,6-tri-O-benzyl-D-glucopyranose
(0.28 g, 0.29 mmol, yield 71 %) as a mixture of two isomers (2:5).
RF = 0.3 (4:1, PE/EtOAc). For the major isomer: 1H NMR (400 MHz,
CDCl3): δ/ppm = 5.34 (d, J = 3.4 Hz, 1 H, H-1′), 4.99–4.50 (m, 13 H,
6 × CH2 Bn, H-1), 4.41–4.28 (m, 2 H, CH2 Bn), 4.15 (d, J = 7.2 Hz, 1
H, H-5), 4.12–4.05 (m, 2 H, H-5′, H-2), 4.00–3.89 (m, 3 H, H-4, H-4′,
H-3′), 3.85 (dd, J = 9.0, 3.4 Hz, 1 H, H-2′), 3.83–3.70 (m, 3 H, H-6′, H-
3), 3.49–3.45 (m, 2 H, H-6). 13C NMR (100 MHz, CDCl3): δ/ppm =
138.7–127.5 (CAr), 96.5 (C-1), 90.3 (C-1′), 80.3 (C-4), 79.0 (C-4′), 77.5
(C-3), 77.3 (CH2 Bn), 75.4 (C-2′), 75.3 (CH2 Bn), 74.8 (CH2 Bn), 74.5
(C-2), 74.3, 73.6, 73.2, 72.5 (4 × CH2 Bn), 70.9 (C-5′), 69.7 (C-5), 68.6
(C-6′), 68.5 (C-6). [α]D20 = +36.7 (c = 1.90, CHCl3). IR: ν̃/cm–1 = 3027,
2901, 1724, 1497, 1453, 1364, 1263, 1208, 1067. HRMS: found
995.4343 [C61H64O11 + Na]+, calculated for [C61H64O11 + Na]+
995.4341. Step 2: LiAlH4 (0.5 mL, 2.4 M in THF, 1.2 mmol) was added
dropwise into a solution of 2-O-(2,3,4,6-tetra-O-benzyl-α-galacto-
pyranosyl)-3,4,6-tri-O-benzyl-D-glucopyranose (0.25 g, 0.26 mmol) in
THF (3 mL) at 0 °C under argon atmosphere. After stirring overnight,
the reaction mixture was slowly quenched with methanol, after
which HCl (1 M, 3 mL) was added. Then the mixture was diluted
with EtOAc and washed with brine, the water layer was extracted
with EtOAc. The organic layer were combined, dried (Na2SO4), fil-
tered and concentrated. The crude product was purified with silica
gel column chromatography (2:1 → 1:1, PE/EtOAc) to gain 2-O-
(2,3,4,6-tetra-O-benzyl-α-galactopyranosyl)-3,4,6-tri-O-benzyl-D-
glucitol (0.22 g, 0.23 mmol, yield 88 %). RF = 0.58 (1:1, PE/EtOAc).
1H NMR (400 MHz, CDCl3): δ/ppm = 5.05 (d, J = 3.5 Hz, 1 H, H-1′),
4.96–4.86 (m, 2 H, CH2 Bn), 4.79–4.51 (m, 6 H, 3 × CH2 Bn), 4.45 (d,
J = 12.0 Hz, 1 H, CHH Bn), 4.35 (d, J = 12.0 Hz, 1 H, CHH Bn), 4.14–
4.04 (m, 2 H, H-2, H-5′), 4.11 (dd, J = 10.1, 3.7 Hz, 1 H, H-2′), 4.00–
3.98 (m, 1 H, H-5), 3.98 (dd, J = 10.1, 2.6 Hz, 1 H, H-3′) 3.92–3.82 (m,
3 H, H-3, H-4′, H-4), 3.81–3.76 (m, 1 H, H-6a), 3.76–3.71 (m, 2 H, H-
6′), 3.69–3.64 (m, 1 H, H-6b), 3.52 (dd, J = 9.3, 6.7 Hz, 1 H, H-1a),
3.38 (dd, J = 9.4, 5.8 Hz, 1 H, H-1b). 13C NMR (100 MHz, CDCl3):
δ/ppm = 138.5–127.5 (CAr), 99.9 (C-1′), 81.8 (C-5), 79.3 (C-3′), 79.2
(C-4′), 79.2 (C-3), 76.2 (C-2′), 74.7 (C-4), 74.6–72.6 (7 × CH2 Bn), 71.2
(C-6′), 70.7 (C-5′), 70.4 (C-2), 69.4 (C-1), 62.5 (C-6). [α]D20 = +39.1 (c =
1.17, CHCl3). IR: ν̃/cm–1 = 3448, 3063, 3029, 2922, 2863, 1724, 1497,
1453, 1359, 1271, 1208, 1076, 1027. HRMS: found 997.4499
[C61H66O11 + Na]+, calculated for [C61H66O11 + Na]+ 997.4497. Step
3: A solution of (COCl)2 (100 μL, 1.16 mmol) in dry DCM (1.5 mL)
was cooled to –78 °C under argon atmosphere. DMSO (100 μL,
1.40 mmol) dissolved in dry DCM (1.5 mL) was added dropwise.
After 40 min 2-O-(2,3,4,6-Tetra-O-benzyl-α-galactopyranosyl)-3,4,6-
tri-O-benzyl-D-glucitol (0.32 g, 0.33 mmol, co-evaporated 3 × with
toluene), in dry DCM (7.5 mL), was added dropwise to the mixture.
The reaction was stirred for 2 hours at –78 °C, after which Et3N
(0.51 mL, 3.65 mmol) was added dropwise. The mixture was gradu-
ally warmed to –40 °C in 1 h, after which it was poured into a
cooled (0 °C) MeOH solution (60 mL) containing NaCNBH3 (0.09 g,
1.44 mmol), HCOONH4 (0.49 g, 7.76 mmol), and Na2SO4 (0.19 g,
1.34 mmol). The mixture was stirred overnight allowing the reaction
to reach room temperature. TLC analysis showed the formation of
the product (2:1, PE/EtOAc, RF = 0.37). After filtering, the solvents
were evaporated, as the residue was dissolved in EtOAc (100 mL).
The solution was washed with sat. aq. NaHCO3 solution. The organic
layer was dried (Na2SO4) filtered and concentrated. The residue was
purified with silica gel column chromatography (5:1 → 2:3, PE/
EtOAc) to give 2-O-(2,3,4,6-tetra-O-benzyl-α-galactopyrano-
syl)-3,4,6-tri-O-benzyl-1-deoxynojirimycin in 24 % yield (0.07 g,
0.073 mmol). RF = 0.37 (2:1, PE/EtOAc). 1H NMR (400 MHz, CDCl3):
δ/ppm = 4.95–4.80 (m, 7 H, H-1′, 3 × CH2 Bn), 4.72 (d, J = 11.8 Hz,
1 H, CHH Bn), 4.67 (d, J = 12.1 Hz, 1 H, CHH Bn), 4.57–4.44 (m, 4 H,
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2 × CH2 Bn), 4.31 (d, J = 6.2 Hz, 2 H, CH2 Bn), 4.20 (td, J = 6.5, 1.3 Hz,
1 H, H-5′), 4.05 (dd, J = 10.1, 3.6 Hz, 1 H, H-2′), 3.89 (dd, J = 10.1,
2.9 Hz, 1 H, H-3′), 3.75 (dd, J = 9.2, 4.6 Hz, 1 H, H-2), 3.72–3.69 (m,
2 H, H-6a, H-4′), 3.65–3.59 (m, 1 H, H-6b), 3.60 (t, J = 9.2 Hz, 1 H, H-
3), 3.52 (dd, J = 9.6, 6.4 Hz, 1 H, H-6′a), 3.41 (t, J = 9.3 Hz, 1 H, H-4),
3.32 (dd, J = 9.6, 6.6 Hz, 1 H, H-6′b), 3.25 (dd, J = 12.5, 4.8 Hz, 1 H,
H-1e), 2.76 (ddd, J = 9.3, 5.0, 2.6 Hz, 1 H, H-5), 2.56 (dd, J = 12.5,
10.4 Hz, 1 H, H-1a). 13C NMR (100 MHz, CDCl3): δ/ppm = 138.8–
127.5 (CAr), 94.5 (C-1′), 85.9 (C-3), 80.4 (C-4), 78.7 (C-3′), 76.5 (C-2′),
75.6 (CH2 Ph), 75.2 (C-4′), 75.2 (CH2 Bn), 74.8 (CH2 Bn), 74.8 (C-2),
7 3 . 7 ( C H 2 B n ) , 7 3 . 5 – 7 2 . 9 ( 4 × C H 2 B n ) , 6 9 . 8 ( C - 6 ) , 6 8 . 9
(C-6′), 68.8 (C-5′), 59.7 (C-5), 46.5 (C-1). [α]D20 = +76.9 (c = 0.32,
CHCl3). IR: ν̃/cm–1 = 2990, 2901, 1453, 1394, 1241, 1066, 1057, 1028.
HRMS: found 956.4735 [C61H65NO9 + H]+, calculated for [C61H65NO9
+ H]+ 956.4732. Step 4: 2-O-(2,3,4,6-Tetra-O-benzyl-α-galacto-
pyranosyl)-3,4,6-tri-O-benzyl-1-deoxynojirimycin (0.2 g, 0.21 mmol)
was dissolved in ethanol (6 mL), pH of the solution was adjusted to
2 with 1 M HCl. Pd/C (10 %) was added, the mixture was shacked
under H2 atmosphere at 4 bar for 24 h. The catalyst was filtered
through a pad of celite and the solution was concentrated. The
residue was purified on gel-filtration column chromatography (elu-
ent: NH4Ac, 0.15 M, aq.) to obtain pure 29 (35 mg, 0.11 mmol, yield
52 %). 1H NMR (400 MHz, D2O): δ/ppm = 4.93 (d, J = 3.8 Hz, 1 H, H-
1′), 4.05 (t, J = 6.4 Hz, 1 H, H-5′), 3.85 (d, J = 3.2 Hz, 1 H, H-4′), 3.80
(dd, J = 12.8, 3.1 Hz, 1 H, H-6a), 3.77–3.70 (m, 3 H, H-6b, H-2, H-3′),
3.68 (dd, J = 10.5, 3.7 Hz, 1 H, H-2′), 3.58 (d, J = 6.2 Hz, 2 H, H-6′),
3.54 (dd, J = 12.6, 5.0 Hz, 1 H, H-1a), 3.52–3.49 (m, 2 H, H-3, H-4),
3.06 (ddt, J = 8.0, 5.4, 3.1 Hz, 1 H, H-5), 2.84 (dd, J = 12.5, 11.5 Hz,
1 H, H-1b). 13C NMR (100 MHz, D2O): δ/ppm = 100.0 (C-1′), 74.4
(C-3), 71.6 (C-3′), 70.9 (C-5′), 69.0 (C-2), 69.0 (C-4′), 67.8 (C-2′), 67.6
(C-4), 60.8 (C-6′), 59.8 (C-5), 57.6 (C-6), 43.2 (C-1). [α]D20 = +66.0 (c =
0.10, MeOH). IR: ν̃/cm–1 = 3320, 2954, 2842, 1634, 1393, 1148, 1080,
1014. HRMS: found 364.1010 [C12H23NO9 + K]+, calculated for
[C12H23NO9 + K]+ 364.1004.
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